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ABSTRACT  
 
Signaling events that converge on the activation of the TOR/S6K pathway have 
been shown to be critically related to growth. Recent investigations on the molecular 
network controlling growth have revealed that Drosophila melanogaster constitutes an 
efficient alternative model to the mammalian system. As the nature of interactions 
between known components of the pathway is becoming more understood, it is clear 
that a number of elements are lacking.  Recently the Thomas laboratory initiated an EP 
screen in Drosophila utilizing a unique phenotype in the wing, where the yeast Gal-4 
promoter was used to drive expression of random genes in the dorsal wing 
compartment of the flies.  An enhancement of growth in this tissue could then be 
observed by curvature of the wing.  When UAS dS6K is driven with apterous- GAL4 
in Drosophila, a bent-down wing phenotype is observed.  By screening of random EP 
insertions combined with UAS dS6K, a number of enhancers were discovered, two of 
which are presented in this thesis.  We show that both orb2 and IP3K1 are genes which 
have a role in the control of growth, and provide models which can help to explain 
their role in S6K/TOR signaling. 
 
 xii 
ABBREVIATIONS 
4E-BP1  eIF4E binding protein 1 
dS6K  Drosophila S6 kinase 
dTOR  Drosophila Target of Rapamycin 
EP  enhancer–promoter 
IR   Insulin receptor 
IP3   Inositol (1,4,5)Phosphate 
IP4   Inositol(1,3,4,5)Phosphate  
IP3K  Inositol Phosphate -3 Kinase 
IRS   Insulin receptor substrate 
GAP   GTPase-activating protein 
mRNA  messenger RNA 
mTOR  Mammalian target of rapamycin 
Orb1  oo18 RNA-Binding Protein 1 
Orb2  oo18 RNA-Binding Protein 2 
PDK1   PtdIns(3,4,5)P3-dependent protein kinase-1 
PI(3)K  phosphatidylinositol-3 kinase 
PIP2   Phosphatidylinositol(4,5) Phosphate 
PIP3   Phosphatidylinositol (3,4,5) Phosphate 
PKB   Protein Kinase B 
Rheb  Ras Homologue Enriched in Brain 
RNAi   RNA mediated interference 
S6   40S ribosomal subunit protein 6 
S6K1   S6 kinase 1 
S6K2   S6 kinase 2 
TOR   Target of Rapamycin 
TSC   Tuberous Sclerosis Complex 
UTR   Untranslated region 
Less frequently used abbreviations are defined upon their first use in the text. 
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CHAPTER 1: Introduction and Background 
 
1.1 Growth 
Cellular growth 
The successful development of a multicellular organism relies on fine-tuned 
events controlling cellular growth, differentiation, proliferation, and death.  The 
number and size of cells ultimately dictates the size of the organism [1]. At the most 
basic level, final cell size is limited by its volume to surface area ratio, and there comes 
a point in the growth of a cell when its surface area is insufficient to meet the demands 
of the volume of the cell.  Two daughter cells generated by mitosis, which are initially 
the half size of the mother cell, must grow before they can undergo the next round of 
cell division, a process controlled by the cell cycle.  For this reason it has been 
rationalized that progression through cell-cycle is a mediator of growth regulation.  To 
the contrary, it has been shown that proliferation is determined by growth, and not vice 
versa [2, 3].  
Given the coordination of mitosis with growth and cell cycle, it is easy to 
understand why it has been long proposed that cell size is tightly linked to DNA 
content [4].  However, there is an obvious limitation to this paradigm, which is that 
metazoans may have many different cell types of variable size, but with constant DNA 
content.  In fact, the growth rate of a cell must be proportional to its cellular content or 
‘dry mass’.  Since the majority of this dry mass is accounted for by proteins, it is 
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reasonable to assume that the important factors for increased cell size would be those 
important for the synthesis of proteins, such as ribosomes.  Ribosomes are vital 
organelles that catalyze protein synthesis, and in eukaryotes are composed of four RNA 
molecules and one molecule each of 79 different proteins (‘ribosomal proteins’) [5].  It 
has been shown in Drosophila that the amount of protein in a cell is in fact dependent 
upon ribosomal RNA content, whose synthesis requires RNA polymerase I [6].  Of 
course, without a source of the essential amino acids required for protein synthesis, this 
process would also be limited and therefore nutrient input is also essential for growth. 
 
Cell cycle control 
Cell division is an evolutionarily conserved process requiring tight spatial and 
temporal control of its molecular events. An intricate network of regulatory pathways 
ensures that each cell cycle event is performed correctly and in proper sequence, 
leading to the replication of chromosomal DNA and equal distribution of duplicated 
DNA between two daughter cells [7]. The mammalian cell cycle can be divided into 
five phases: G0, G1, S, G2 and M.  These phases are categorized as ‘Gap’, ‘Synthesis’, 
and ‘Mitosis’ phases.  A cell in the G0 phase is in a quiescent state, and will remain so 
until external stimuli trigger signaling events such as the activation of the ras-
dependent extracellular signal-regulated kinase 1 (ERK1)/2 mitogen-activated kinase 
(MAPK) cascade, which plays a central role in cell proliferation [8].  MAPKs are 
serine-threonine protein kinases that are activated by diverse stimuli ranging from 
cytokines, growth factors, neurotransmitters, hormones, cellular stress, and cell 
adherence[9].  In the case of cell cycle regulation, the small GTPase Ras is activated 
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following cell surface receptor activation, which recruits the MAP kinase kinase kinase 
Raf to the membrane for subsequent activation by phosphorylation.  Raf then activates 
the MAP kinase kinases MEK1/MEK2, which in turn activate effector MAP kinases 
ERK1 and ERK2 [9].  ERK1/2 activity is necessary for G1- to S-phase progression and 
is associated with induction of positive regulators of the cell cycle and inactivation of 
anti-proliferative genes [8]. 
 Signaling events triggered by the binding of growth factors to cell surface 
receptors cause the cell to exit G0 and re-enter the cell cycle at G1, where synthesis of 
the mRNAs and proteins required for DNA synthesis will take place before progression 
into S-phase [10].   Upon entry into G1 phase, progression of the cell through each 
phase of the cell cycle is dependent upon the sequential formation, activation, and 
inactivation of cell cycle control molecules.  These include the cyclin (regulatory 
subunit) and cyclin-dependent kinase (Cdks, catalytic kinase subunit) complexes, 
which are regulated at the level of transcription, translation, and post-translational 
modification [10].  The first of these complexes consists of the D-type family of 
cyclins (D1, D2, and D3) plus Cdk4/6 and allows the cell to exit G1.  Cyclins A and E 
pair with Cdk2 for the G1/S transition and progression through S phase, while Cdk1 
governs the G2/M transition in complex with cyclin B1 [11].  Studies in knock out 
animal models indicate that loss of the catalytic member of these complexes can be 
compensated for by other Cdk isozymes and cell cycle progression continues.  For 
example, despite their small size and tissue-specific defects, Cdk4 knockout mice are 
viable [12], as are Cdk2 knockouts [13].   
 4 
In complex with D-type cyclins, Cdk4 phosphorylates G1-specific substrates, 
including the retinoblastoma protein (Rb) [14]. Unphosphorylated or 
hypophosphorylated forms of Rb form transcriptional repressor complexes with E2F-
1–3 [15]. Rb phosphorylation in collaboration with cyclin D/Cdk4 and cyclin E/Cdk2 
activity results in release of Rb from the E2F complex, leading to transactivation of the 
E2F target genes important for the S-phase [16]. Highlighting the importance of Rb  
phosophorylation in the cell cycle whilst illustrating the compensation between Cdk2 
and 4, mice deficient in both Cdk2 and Cdk4 are embryonic (E15) lethal. Studies 
carried out in Cdk2-/-, Cdk4-/- Mouse Embryonic Fibroblasts (MEF) revealed a 
decreased proliferation rate, impaired S phase entry, and premature senescence due to 
hypophosphorylation of Rb, which was rescued by inactivation of the protein [17].  
Throughout the cell cycle, control mechanisms exist which impose a dependency of a 
particular event on the completion of the preceding event to ensure correct timing of 
the cell cycle.  Following completion of all steps, the cell can enter mitosis [18]. See 
Figure 1. 
 
The role of Growth and Proliferation in Drosophila development 
In Drosophila, two striking alterations to the classical conserved cell cycle 
exist.  Cells in the early fly embryo exhibit simple, rapid and synchronous cell cycles, 
similar to those seen in Xenopus [19], consisting only of alternating S and M phases 
driven exclusively by maternal factors.  This partitions the egg into smaller and smaller 
cells.  This growth-independent strategy used by the fly during embryogenesis to create 
the emergent first instar larva is in contrast to the growth-linked process used to  
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Figure 1: The conserved eukaryotic regulatory pathways that regulate cell-cycle 
progression. 
Two cell-cycle checkpoints control the order and timing of cell-cycle transitions (G1S 
and G2M), ensuring that critical events such as DNA replication and chromosome 
segregation are completed correctly before cell cycle progression. A major cell-cycle 
restriction point (R) is located at the end of the G1 phase, after which, precursors will 
invariably complete the cycle. Mitotic cycle progression is driven by the actions of 
CDKs and their activating cyclin subunits, CDK activity is suppressed through the 
INK4 family (that exhibits selectivity for CDK4 and CDK6) and the CIP/KIP family (a 
broader range of CDK inhibitory activity). The rate of cell-cycle progression is 
determined by the relative abundance of positive and negative regulators.  
This figure was adapted from; "Cell-cycle control and cortical development", Dehay & 
Kennedy, Nature Reviews Neuroscience 8, 438-450 (June 2007 
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generate the adult fly which develops from imaginal cells nurtured by the larva [20].   It 
is not until later in embryogenesis that the cell cycle incorporates a G1 phase, linking 
cell cycle progression to extracellular cues and allowing for coordination of growth and 
division. This phase occurs after the disappearance by proteosomal degradation of 
maternally transcribed cdk activators, which are zygotically transcribed once the 
embryo enters a cell-cycle containing a growth phase.   
Endoreplication conversely, entails rounds of S- and G- phases exclusively, as a 
strategy for cellular growth without mitosis in the larval stages.  In some 
endoreplicative cells, levels of G2-M phase machinery such as cyclins B and A, and 
Cdk1 have been found to be either absent or present at very low levels.  It is clear that 
cyclin E/Cdk2 kinase plays a major role in endocycling, with induction of cyclin E 
triggering precocious DNA replication in such tissues.  On the other hand, continuous 
over-expression of cyclin E inhibits endocycle progression, leading to the suggestion 
that oscillations in cyclin E levels may be important for the process.  In flies, the G1 
cyclins include one D-type and one E-type cyclin, which allosterically activate Cdk4 
and Cdk2, respectively. Unlike cyclin E and Cdk2, neither cyclin D nor Cdk4 is 
essential for viability in Drosophila, and mutant flies lacking the latter genes develop to 
adulthood, although they exhibit a loss of fertility and small size [21, 22]. Therefore, 
not all of the cell cycle proteins that contribute to G1-phase regulation are obligate 
components of the cell division machinery, but rather couple the activity of the core S- 
and M-phase oscillator to diverse mitogenic signal transduction pathways [23]. 
In contrast to the unusual cell-cycle alterations outlined above, Drosophila 
imaginal discs, the epithelial sheets which will later form the adult structures, undergo 
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classical cell division cycles, coupled to an extensive increase in the size of the disc by 
growth [24].  An example of this is in the imaginal wing disc, whose development is 
discussed later. 
 
1.2 Intracellular signaling 
Intracellular Signal Transduction 
The activation of a cell surface receptor by the binding of an extracellular 
ligand triggers a series of events which elegantly coordinates cell signaling pathways 
for metabolism, growth and survival with the organism’s surroundings. The evolution 
of such coordination has allowed multicellular organisms to succeed in adapting to a 
dynamic environment in terms of nutrient availability, temperature change and 
pathogenic invasion.  The extracellular molecules involved in regulation of cell 
processes can be arranged into diverse classes (Table 1).  Binding of ligand to the 
external portion of an integral plasma membrane receptor evokes a conformational 
change within the intracellular domain.  The conformational change initiates signal 
transduction by activating the enzymatic activity of the receptor or by exposing binding 
sites for other proteins.  Downstream components of these pathways usually possess 
enzymatic activity and include, but are not limited to, heterotrimeric G proteins, small 
GTPases, protein kinases, protein phosphatases, lipid kinases and lipid hydrolases.  In 
addition to modification of existing proteins, second messengers are often produced, 
which play a powerful role in the amplification of the signal from the cell surface.   
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Class Example Origin Target Major effect 
Amino acid- 
derived 
Serotonin Platelets Arterioles 
Venules 
Vasodilation 
Increased vascular 
permeability 
 
Peptide hormones Glucagon Pancreatic 
α-cells 
Liver 
Adipose tissue 
Glycogenolysis 
Lipolysis 
 
Growth factors Epidermal 
Growth Factor 
(EGF) 
 
Multiple 
cell types 
Epidermal and 
other cells 
Growth 
Eicosanoids Prostaglandins Most body 
cells 
 
Multiple Inflammation 
Vasodilation 
Membrane 
permeant 
hormones 
Progesterone Corpus 
Luteum 
Placenta 
Uterine 
endometrium 
Preparation of 
endometrial layer 
Maintenance of 
pregnancy 
 
 
Table 1: A selection of first messengers found in the circulation.   
Adapted from “Signal Transduction”, Gomperts, Kramer& Tatham, Elsevier 2003. 
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Protein modification and second messengers 
Post-translational modification of proteins ranges from the addition of other 
proteins or peptides, addition of functional groups, changes in the chemical nature of 
amino acids, or structural changes.  Major second messengers in a cell are cyclic AMP 
(cAMP), calcium ions (Ca2+), diacylglycerol, and the 3-phosphorylated inositol lipids, 
all of whom’s role is to amplify a signal from the plasma membrane via modification 
of existing proteins or molecules in the cell [25].  A key regulatory modification in the 
rapid transduction of a signal in eukaryotes is protein phosophorylation, the addition of 
a phosphate group (PO4) from a nucleotide triphosphate (such as ATP) to a serine, 
tyrosine or threonine residue, which can affect protein structure and polarity thus 
activating or inactivating a protein, or induce changes in protein structure that alters 
docking potential for other proteins. 
 
1.3 The PI3K/TOR/S6K signaling pathway 
S6 Kinase and Target of Rapamycin proteins 
S6 kinase (S6K) was originally described as a kinase responsible for 
phosphorylation of ribosomal protein S6, isolated from Swiss mouse 3T3 cells [26], 
with identification of two isoforms shortly after [27, 28].  The shorter form, originally 
termed p70S6K, is largely cytoplasmic, while the longer form, originally termed p85S6K, 
contains a nuclear localization signal, and speculation exists for a role of the nuclear 
form in phosphorylation of chromatin-bound S6 [29].  Since the identification of S6K2 
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as a second S6 Kinase [30], the p70S6K and p85 S6K isoforms (recently termed S6K1S 
and S6K1L, respectively) of the original gene are collectively known as S6K1.  Both 
S6K1 and S6K2 display kinase activity which is inhibited by treatment with the 
macrolide rapamycin (see below), or by phosphatidylinositol 3OH-kinase (PI3K) 
inhibitors. 
The Target of Rapamycin (TOR) is a member of the PI3K-related family of 
protein kinases, along with ATM, ATR and DNA-dependent kinase, by virtue of 
similarity in its kinase domain [31].  This family of kinases is largely involved in cell-
cycle checkpoint signaling related to DNA damage [32].  A large protein of ~280kDa, 
mTOR has been documented as having several other domains, important for regulation 
of the kinase and protein-protein interactions [33].  TOR proteins are so-called due to 
their specific inhibition by the macrolide rapamycin, a drug which until recently has 
been used as an immunosuppressant in transplant patients, and derivatives are now in 
clinic for renal cell carcinomas and clinical trials for use as an anti-cancer treatment 
[34-36].  When Rapamycin is added to cells, it forms an inhibitory “gain-of-function” 
complex with the FK-506 Binding Protein 12 (FKBP12) and TOR [37, 38]. 
During evolution of higher mammals the TOR signaling pathway has gathered 
complexity, and is considered to be a major point of integration for controlling growth, 
in relation to nutrient availability [31].  This control is largely mediated through 
translation, the production of proteins from an mature messenger RNA template [39], 
and autophagy, a process in which parts of the cytoplasm, including entire organelles, 
are first sequestered in vacuoles and then destroyed through a lysosomal pathway [40, 
41].  TOR signaling has two major extra cellular inputs, growth factors and nutrients, 
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such as amino acids and glucose.  Two distinct signaling complexes exist that are often 
referred to as the rapamycin-sensitive complex and the rapamycin-insensitive complex, 
and whose pathways cross-talk at several points.   
 
The two TOR complexes; TOR complex 1 and TOR complex 2 
The first hint at the existence of two independent TOR signaling complexes 
was in Saccharomyces cerevisiae, when two genes, TOR1 and TOR2 were identified  
on the basis of their sensitivity to rapamycin [42].  These genes were later identified as 
present in two complexes; a rapamycin-sensitive complex (TOR complex 1) formed 
with either TOR1 or TOR2 along with newly described proteins KOG1 and LST8, and 
a rapamycin-insensitive complex (TOR complex 2), formed only with TOR2, AVO1, 
AVO2, AVO3 and LST8 [43].  In other eukaryotes, a single TOR gene exists, and thus 
the two TOR complexes are formed only with one TOR protein that is the functional 
homolog of yeast TOR2 [44].   
TOR binding partners identified in yeast have now been shown to have 
conserved counterparts in mammals, and invertebrates.  TOR complex 1, which is 
sensitive to rapamycin, is a complex of mTOR with GβL and Raptor (in yeast; LST8 
and KOG1 respectively)  [45, 46].  More recently mammalian PRAS40 (proline-rich 
Akt (PKB) Substrate 40 kDa; for PKB, see below), has been demonstrated to 
preferentially bind Raptor, thereby inhibiting complex 1 activity [47].  This result has 
been controversial, with other laboratories claiming that PRAS40 is a substrate for 
TOR complex 1, and competes with other substrates for binding and phosphorylation 
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by TOR [48-50].  PRAS40 contains a TOR signaling (TOS) domain [48, 49], a 
conserved five amino acid sequence that is crucial for their regulation by the mTOR 
pathway [51].  Other substrates of complex 1 also contain this TOS motif, such as 
S6K1 and the eIF4E binding protein which inhibits translation, 4E-BP1 [51].  A 
common readout for the activity of TOR complex 1 is phosphorylation of S6K1 at 
threonine 389.  S6K1 requires this threonine 389 (T389) phosphorylation a C-terminal 
hydrophobic motif by TOR complex 1, for activity, as it serves as a docking site for the 
phosphoinositide-dependent protein kinase 1 (PDK1), which phosphorylates T loop of 
and leads to S6K1 activation [52].  
TOR complex 2, which is resistant to short-term rapamycin inhibition, is a 
complex of mTOR with, GβL, Rictor and SIN1 (in yeast; LST8, AVO3, and AVO1 
respectively) [53-55].  GβL, Rictor, and SIN1 are all required for TOR complex 2 
activity, as removing one of these components destabilizes the complex [44].  
Recently,  Protor-1 (protein observed with Rictor-1) and Protor-2 have been identified 
as binding partners of complex 2  [56], along with PRoline-Rich protein 5 (PRR5) [57], 
but so far, little is known about these interactors.  Importantly, long term rapamycin 
treatment is reported to have an effect on TOR complex 2 by inhibition of new 
complex formation [58].  The main readout for TOR complex two activity is 
phosphorylation of protein kinase B, which is phosphorylated by TOR complex 2 at 
serine 473 (S473) [59].  PKB was originally reported as a cellular counterpart of the 
viral oncogene v-Akt, and its over-expression or increased activity has been implicated 
in a wide range of cancers [60].  Recently, the importance of this gene in cancer was 
highlighted by the discovery of a somatic mutation in the PH-domain (see below) of 
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PKB found in human breast, colorectal and ovarian cancers that transforms cells and 
induces leukemia in mice [61]. 
Drosophila homologues of most these complex components have been 
identified (with the exceptions of the most recent discoveries PRR5 and Protor) and 
current data agrees with observations in mammalian cells [47, 52, 62].  
 
The mammalian PI3K/TOR/S6K signaling pathway 
PI3K/TOR/S6K signaling begins at the plasma membrane by ligand binding-
induced activation of a cell surface receptor.  In the case of insulin to the Insulin 
Receptor (IR), this results in recruitment of Insulin Receptor Substrates (IRS) to the 
cell membrane [63] and subsequent recruitment and activation of a class 1 PI3K, a lipid 
kinase that converts PtdIns(4,5)P2 (PIP2) to the potent second messenger 
PtdIns(1,4,5)P3 (PIP3) at the plasma membrane [64].  The production of PIP3 by PI3K 
is antagonized by two phosphases, PTEN (the phosphatase and tensin homolog on 
chromosome 10), which dephosphorylates PIP3 at the ‘3’ position, and ), SHIP (SH2-
domain-containing inositol-5-phosphatase) dephosphorylates PIP3 at the ‘5’ position, in 
both cases generating different forms of PIP2 [65, 66].  PIP3 binds to the pleckstrin 
homology domain (PH domain) of several proteins such as PDK1 and Protein Kinase B 
(PKB), resulting in their recruitment to the cell membrane. Upon localization to the 
membrane PDK1 phosphorylates the critical site T308 on PKB [67]. PKB is fully 
activated by further phosphorylation at S473 by TOR complex 2, allowing it to signal 
to its downstream substrates [59].  One of these substrates is the tumor suppressor 
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tuberous sclerosis complex 2 protein (TSC2), phosphorylation of which leads to the 
degradation of the TSC1&2 complex [68]. The TSC1/2 complex acts as a GTPase 
Activating Protein (GAP) inhibiting the small GTPase Ras Homologue Enriched in 
Brain (Rheb) by driving it into the inactive GDP bound state [69, 70].  Alone, Rheb has 
very low intrinsic GTPase activity, thus degradation of the TSC1/2 complex relieves 
Rheb of the suppressive GAP regulation resulting in the active GTP bound state. GTP 
bound Rheb is able to signal to TOR complex 1 through direct binding [71]. Thus 
growth factors such as insulin are able to use this canonical cascade to activate raptor-
mTOR through a PI3K dependent mechanism.  
The raptor-mTOR complex is also regulated by amino acids and glucose 
through a PI3K dependent pathway, however this does not appear to be orchestrated by 
the activity of class I PI3K but rather class III PI3K [72, 73].  The amino acid input to 
TOR complex 1  is completely dominant to the growth factor input where, in the 
absence of these nutrients, phosphorylation of TOR complex 1 substrates does not 
occur even in the presence of insulin [73, 74]. Until only recently the cascade involved 
in the amino acid stimulation of raptor-mTOR remained largely unknown. Based on 
the sensitivity to PI3K inhibitors of this arm of the pathway and a number of elegant 
loss and gain of function experiments, Nobukuni et al eliminated a role for the PI3K-
Akt-TSC1/2 signaling axis in the activation of Rheb and introduced the class III PI3K 
hVps34 as the mediator of the amino acid signal to TOR complex 1 [73]. An active 
TOR complex 1 is required for phosphorylation of several components of the ribosome 
recruitment machinery, some of which are indirect through S6K activity [33, 75-78].  
See Figure 2. 
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Figure 2:  The TOR/S6K Signaling Pathway.   
See text for explanation of pathway. 
Adapted from “mTOR Complex1–S6K1 signaling: at the crossroads of obesity, 
diabetes and cancer” Dann,S. G. et al, Trends in Molecular Medicine,Volume 13, 
Issue 6, June 2007, Pages 252-259 
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Conservation of the pathway  
Although there are differences between mammalian and invertebrate models of 
S6K/TOR signaling, the pathway is highly conserved in Drosophila, and several key 
regulators were discovered through this model organism; for example, Rheb and 
TSC1&2 [79-81].  The initial implication of insulin signaling in the control of cell size 
in Drosophila was provided by the laboratories of Sally Leevers and Ernst Hafen, who 
demonstrated that PI3K (p110) and IRS (chico) are required cell-autonomously to 
promote cell growth (see below) [82].  The Drosophila TOR protein (dTOR) is 
required for normal growth and proliferation during larval development, and for 
growth factor-induced Drosophila S6K (dS6K) phosphorylation [83-85].   Drosophila 
has a single receptor system for signaling though drosophila insulin-like-peptides 
(DILPs) and insulin-like growth factor (IGF), and upon binding of either ligand, the 
Drosophila Insulin Receptor (InR) tyrosine kinase becomes activated leading to the 
recruitment of Chico, the Drosophila homologue of IRS1-4 [86].  Chico mutants are 
less than half the size of wild-type flies, owing to fewer and smaller cells [87].  The 
viability of these flies, despite the InR null mutant being embryonic lethal, could be 
due to an extended C-terminal portion of the InR receptor that contains multiple PI3K 
sites that could contribute to low level insulin/IGF signaling levels [88].  As in 
mammals, PI3K plays a central role in the Drosophila insulin signaling pathway with 
the generation of second messenger PIP3 from PIP2 [89].  The monomer dp60 is the fly 
orthologue of the mammalian p85 regulatory subunit of PI3K, and upon over-
expression, acts to inhibit PI3K in a dominant-negative manner [90, 91].  In 
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Drosophila, an orthologue of PTEN (dPTEN) antagonizes PI3K activity to suppress 
growth [92], along with Susi, a protein with a coiled-coiled domain that interacts with 
the dp60 regulatory subunit of dPI3K, regulating its activity [93].  Over-expression of 
Susi produced a reduction in organismal, tissue and cell-size, along with a reduction in 
rate of proliferation, and a starvation-resistance phenotype, while all heteroallelic 
combinations of Susi mutants resulted in adult flies with reduced viability and 
increased body size.  Based on the relatively weak loss-of function phenotype 
observed, Wittwer et al postulated that Susi is involved in fine-tuning the cellular 
response to insulin [93]. 
Downstream of PI3K, studies in Drosophila revealed that the S6K1 and S6K2 
orthologue, dS6K, is a negative effector of dPKB activation, which suggested for the 
first time that S6K regulates PKB phosphorylation, which was soon replicated in 
mammalian experiments [85, 94].  DPDK1 action downstream of insulin receptor 
signaling conforms to the mammalian pathway in terms of  phosphorylation of both 
dS6K and dPKB [95].  In 2001, the importance of two additional suppressors of 
insulin-receptor mediated growth became apparent; tuberous sclerosis 1 and 2 
(dTsc1&2) [96].  These two proteins are binding partners in the tumor suppressor 
complex TSC, which has a conserved function in regulation of Rheb and the TOR 
complex 1 [82], as outlined in the mammalian section above.  In addition to the above, 
the Drosophila S6K/dTOR pathway is also negatively regulated in an oxygen-sensitive 
manner by Scylla and Charybdis.  Simultaneous loss of Scylla and Charybdis under 
normoxic conditions resulted in a slight increase in growth, whereas their absence 
under reduced oxygen concentrations severely compromised larval development, 
 18 
indicating that Scylla and Charybdis have a critical function for survival under hypoxic 
conditions [97].  Growth inhibition of these mutants was associated with a reduction in 
dS6K but not dPKB activity.  Under conditions of low oxygen, the transcription factor 
HIF-1 is stabilized as a complex, and binds to short regulatory hypoxia response 
elements (HRE) in the genomic region of target genes [98].   Reiling et al. showed that 
Scylla is a proven target of the hypoxia-inducible factor-1 (HIF-1), like its mammalian 
counterpart, REDD1 [99], which has concurrently been proven to inhibit mTOR 
signaling through a TSC-dependent mechanism [100].  
 
The dS6K null  phenotype in Drosophila 
Loss of dS6K in the adult fly (as described by Montagne et al [101]), generated 
by an imprecise excision of a P-element insertion in the 5’ non-coding region resulted 
in partial lethality (dS6Kl-1).  Homozygous escapers had a five-day developmental 
delay, and lived no longer than two weeks, with a reduction in body size.  The P-
element insertion prior to removal was female sterile, with a three-day delay, indicating 
that an intact dS6K gene is required for normal development.  Analysis of cell number 
was carried out using the individual hairs on the adult wing as a guide to cell density.  
From this, it could be seen that cells were around 30% smaller in the dS6Kl-1 flies, 
while cell number over the entire wing remained the same.  As discussed later, 
imaginal discs give rise to adult structures [102], and because of the mode of 
development the size of the adult wing is largely predetermined by the final size of the 
wing disc [103].  Therefore, fluorescence-activated cell-sorter (FACS) analysis of cells 
from imaginal discs was performed to understand if the cell size reduction was due to 
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proliferation at a smaller size, and if there was a particular phase of the cell-cycle 
involved.  The results showed that while cell-cycle progression proceeded more slowly 
than in wild-type cells, no apparent cell-cycle phase was selectively affected.  The 
growth defects observed were confirmed as cell-autonomous by clonal analysis.  
Genetically marked homozygous mutant cells were generated by the authors in a 
heterozygous mutant background by somatic recombination in first instar larvae to 
create a mosaic animals [104].  Direct comparison of neighboring heterozygous and 
homozygous dS6K mutant wing bristles and ommatidia showed a reduction in bristle 
and photoreceptor size of the mutant clones, indicating that the cell size defect 
observed in the mutant cells was not due to a humoral effect.  Since removal of the 
dS6K gene caused a reduction in cell growth, the authors decided to test if 
compartment-specific expression of an extra copy of dS6K could also enhance growth.  
They found that by using the GAL4 transcription factor under control of the apterous 
promoter, over-expression of a UAS dS6K transgene positively effected growth in a 
cell-autonomous and compartment-dependent manner (see ‘Screening for effectors of 
the pathway’ below for details, and [105] for full explanation of UAS-GAL4 system in 
Drosophila). 
 
S6K/TOR signaling and translation 
Following transcription, processing and nucleo-cytoplasmic export, eukaryotic 
mRNAs are competent for translation.  Translation initiation is the first step in this 
process, and requires several polypeptide initiation factors which serve to direct the 
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sequential assembly and positioning of the ribosome at the AUG initiation codon on 
the mRNA [106].  The major downstream targets of the S6K/TOR signaling pathway 
are involved in translation, especially the translational machinery required for 
ribosomal recruitment to the mRNA [107].  Although no single mechanism controls the 
translation of all mRNAs, emerging evidence indicates that the regulated binding of 
translation initiation factors (eIFs) to the 7-methyl guanosine residue that caps the 5' 
ends of all nuclear-encoded eukaryotic mRNAs is critical [108]. In particular, the 
interaction of the ribosomal-subunit-associated eIF4G with the cap-bound eIF4E is 
necessary for cap-dependent translation, and this association can be prevented by  
eIF4E binding proteins (4E-BPs) [109, 110].  TOR has been shown to phosphorylate 
and inhibit the 4E-BPs, which promotes their dissociation from eIF4E bound to the 
mRNA 7- methyl guanosine cap-structure, thereby allowing for eIF4G association with 
eIF4A recruitment [111, 112].  In addition, eIF4G binds eukaryotic initiation factor 3 
(eIF3), which, in turn, recruits the 40S ribosomal subunit along with its associated 
ternary complex (eIF2/Met-tRNA/GTP) to form the pre-initiation complex [33].  eIF3 
is a complex of at least 12 subunits [113], which interacts with mTOR and S6K1 
intermittently in a growth-factor and rapamycin-sensitive manner [114].  mTOR 
associates with the complex upon mitogen or hormone stimulation, whilst S6K1 
dissociates, promoting the phosphorylation and activation of S6K1 in a coordinated 
fashion.  Phosphorylation of T389 was found to be critical for this process, and once 
released, S6K1 would become fully activated before phosphorylating downstream 
targets ribosomal protein S6, and eIF4B [114, 115].  The consequences of S6 
phosphorylation on translation are still unclear [116], while upon phosphorylation, 
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eIF4B is recruited to the pre-initiation complex in concert with eIF4A [114], a co-
recruitment that potentially increases the RNA-helicase activity of eIF4A [117, 118].  
The RNA helicase activity of eIF4A would allow unwinding of secondary structures in 
the 5′UTR of mRNAs and thereby facilitate binding and scanning of the 40S ribosomal 
subunit [119].   
Along with its role in translation initiation, mTOR has downstream targets 
involved in translation elongation.  The elongation phase of mRNA translation is the 
stage at which the polypeptide is assembled, and requires a set of non-ribosomal 
proteins; eukaryotic elongation factors (eEFs) [120].  In addition to the S6Ks and 4E-
BP1, both of which modulate translation initiation, mTOR signaling regulates the 
translation elongation process via the phosphorylation of eukaryotic elongation factor 2 
(eEF2) [121]. eEF2 is a GTP-binding protein that mediates the translocation step of 
elongation, and when phosphorylated at Thr56, it loses its ability to bind to ribosomes 
and is thus inactivated [122].  Insulin and other stimuli induce the dephosphorylation of 
eEF2, an effect which is is blocked by rapamycin [123]. E2F kinase is a substrate of 
S6K1, as well as several other kinases [124, 125]. 
 
1.4 Screening for effectors of the pathway 
Use of Drosophila  
The TOR/S6K signaling pathway is well studied in a broad range of organisms, 
from yeast through to human [126].  Having covered various aspects of growth, cell 
cycle control, and signaling pathways in earlier paragraphs, it is clear that many 
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important discoveries were made in model organisms.  Drosophila melanogaster is an 
extremely useful tool for investigating the genetic basis of signaling pathways, due to 
its strong conservation of fundamental signaling pathways, such as the insulin-
signaling pathway and the many powerful genetic techniques that have been developed 
over the last 100 years since Drosophila has been used for genetic investigation [127].  
The extent to which genetic methods and tools have been developed for this organism 
far exceeds that for any other complex multi-cellular organism [128].   
In addition, Drosophila particularly lends itself to experimental investigation, 
as it is an organism with a short life cycle, and is easy to maintain. Finally, pathways 
are often simplified in the fly, allowing easier manipulation, for example, whereas two 
S6 Kinases exist in mammals, in Drosophila, there is one [30, 101].   
 
dS6K modifier screen 
The ‘UAS GAL-4’ system uses the yeast GAL-4 transcription factor to induce 
expression of a target gene via an upstream activating sequence (UAS) [105]. Gal-4 
expression can be driven specifically, both temporally and spatially, depending upon 
the specific promoter used to bring about its expression. In this screen described in 
Appendix I, apterous-GAL4 (ap-GAL4) was used to over-express random genes in the 
dorsal wing compartment using an UAS EP (Enhancer-Promoter) construct.   
Imaginal discs give rise to adult structures [102].  A Drosophila adult wing 
develops from a wing imaginal disc, which originates as a group of approximately 30 
cells attached to the inside of the larval epidermis, corresponding to two adjacent 
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clonal compartments (anterior and posterior) and after a quiescent period of just over a 
day, starts dividing [129].  This proliferation continues up to 24 hours after pupariation, 
and during this period the disc becomes subdivided once more into dorsal and ventral 
compartments.  By the time  the animal reaches metamorphosis, the disk has grown in 
cell number 1000-fold, with only two net cell-size reduction divisions to follow in the 
early pupal stage [130].  Due to the mode of development, the size of the adult wing is 
largely predetermined by the final size of the wing disc [103].  
If the growth or proliferation process is disrupted in the dorsal or ventral 
compartment compared to the other, the resulting difference in size will cause a 
discrepancy leading to a phenotypic change (Fig. 3),  This is because the dorsal and 
ventral components of the wing fold in an apposed manner to generate the flattened 
wing [131, 132].  For example, in the case of ap-GAL4-induced UAS dS6K over-
expression, which drives expression of an extra copy of dS6K in the dorsal 
compartment of the wing blade, a bent-down wing phenotype is observed [85, 101].  
Using this sensitive phenotype, differences between cell number and cell size are not 
readily identifiable.  However, the ability of random genes to alter this ap-GAL4, UAS 
dS6K bent-down wing phenotype upon co-over-expression with dS6K was used as a 
readout to identify possible upstream and downstream effectors of dS6K function (see 
Appendix I).  
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Figure 3: Apterous-GAL4 induced growth causes bending-down of the wing.  
Top panel: Apterous-GAL4 is used to drive a growth-promoting agent in the dorsal 
wing compartment, resulting in a bending down of the wing due to either an increase in 
cell number, or cell size. Lower panel: an example of ap-GAL4; UAS dS6K induced 
growth, with enhancement by co-over-expression with UAS DPDK1. 
Lower panel adapted from; dS6K-regulated cell growth is dPKB/dPI(3)K-independent, 
but requires dPDK1, Thomas Radimerski et. al. Nature Cell Biology  4, 251 - 255 
(2002) 
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Candidates 
Based on their phenotypic enhancement, we decided to look closely at two 
candidate enhancers of ap-GAL4, UAS dS6K mediated growth, and their potential for 
modification of the pathway.  This thesis addresses two candidates, which will be 
discussed in separate chapters.  The first is the Drosophila oo18 RNA-binding protein 
2 (orb2), which is a homologue of the mammalian CPEB family of proteins, which are 
known for their role in translation.  The second is Inositol Phosphate-3 Kinase 1 
(IP3K1), which is an inositide kinase with relevance to second messenger generation in 
calcium signaling. 
 
1.5 Aims of the Project 
As the nature of interactions between known components of the TOR/S6K 
pathway is becoming more understood, it is clear that a number of elements are 
lacking.  Our aim was to use the model organism Drosophila melanogaster as a tool to 
elucidate novel components of the pathway, and to find a link with their mammalian 
counterparts in hopes of better understanding a pathway with implications for human 
disease. 
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CHAPTER 2: MATERIALS AND METHODS 
 
2.1 Supplies 
Ampicillin, Sigma Antimycotic: GIBCO, Benzamadine hydrochloride: Sigma, 
Bis- acrylamide: Biorad, Bradford Reagent: Biorad, Drosophila Schneider’s media: 
Gibco, Foetal bovine serum, Hyclone, Insulin: sigma, Pepstatin; sigma, 
Phenylmethylsulfonylflouride: sigma, Nitrocellulose membranes: Whatman, 
Restriction enzymes; New England Biolabs, RNAsin: Promega, Taq Polymerase and 
Buffer A; Fisher. IP3 Kinase inhibitor; Calbiochem. 
 
2.2 Drosophila Experiments 
Fly stocks 
Fly stocks were maintained in a specially conditioned room at 18°C and 62% 
relative humidity.  Stocks were transferred to fresh fly food (yeast supplemented 
cornmeal and molasses) every four weeks.  Small scale experimental crosses were set 
with approximately 10 virgin females and 5 males in 30ml plastic vials, and generally 
kept at 25°C and 70% relative humidity, unless otherwise stated.  Experimental crosses 
were transferred daily into fresh tubes.  Fly stocks used are previously published as 
indicated, except; EP IP3R: Bloomington; y1w67c23;P{EPgy2}Itp-r83AEY02522/TM3, 
Sb1Ser1, and EP dFMR1: Bloomington; w1118; P{EP}Fmr1EP3517. 
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Screening for dS6K modulators 
Over-expression of an extra copy of dS6K within the developing dorsal wing 
compartment using the ap-GAL4 driver induced a bent-down wing in the adult 
(Appendix I, Fig. 1A,B) due to a moderate overgrowth of the dorsal wing blade [101]. 
Consistent with PDK1 being the S6K T-Loop kinase [133, 134], it was further 
observed that this bending-down was enhanced by co-expression of the drosophila 
PDK1 (DPDK1).  Over-expression of DPDK1 alone, however, was without noticeable 
consequence [85]. This epistatic interaction demonstrated that the intensity of the bent-
down wing phenotype was modified with respect to the dS6K activation status. 
Therefore, this sensitized phenotype was used in a gain-of-function genetic strategy to 
identify new components with the potential ability to regulate dS6K activity 
Interestingly, over-expression of an active form of the mammalian S6K (S6K1dE/D3E) 
[135] induced a bent-down wing phenotype identical to that induced by dS6K 
(Appendix I, Fig. 1 B,C). Like dS6K, co-expression of S6K1dE/D3E and DPDK1 led to 
an enhancement of the bent-down wing, but not to the extent observed with dS6K (data 
not shown). This differential phenotypic interaction may be a hallmark of specificity, 
as dS6K, unlike S6K1dE/D3E, is the genuine target for DPDK1 [85, 95]. These 
differential effects were utilized to improve the selectivity of the gain-of-function 
screen (see below). 
Over-expression of About 5000 Enhancer-Promoter (EP) bi-directional 
insertions [97] were induced in combination with dS6K in the developing dorsal wing 
compartment, and the dS6K-dependent bent-down wing phenotype was monitored for 
 28 
enhancement or suppression. To further restrict their specificity, about 1000 EP lines 
that displayed striking phenotypes possibly unrelated to dS6K function were then 
retained and analyzed for their effects when induced alone with the ap-Gal4 driver. 
Nonspecific modulators that, alone, induced a phenotype identical to that obtained in 
concert with dS6K were eliminated. Eventually, 220 lines were tested again to 
precisely compare their effects when induced alone, in combination with dS6K or with 
the active S6K1dE/D3E. The enhancers identified in the screen could be separated into 
two subsets with respect to their interaction with dS6K and S6K1dE/D3E. One subset 
enhanced the bent-down wing phenotype to the same extent in combination with either 
kinase, while the other subset displayed a differential effect that was stronger in 
combination with dS6K than with S6K1dE/D3E (data not shown). As DPDK1 belongs to 
the latter group, we reasoned that candidate enhancers that interacted differentially with 
dS6K and S6K1dE/D3E were more likely to affect dS6K signaling, whereas those with no 
differential response might be involved in the general process of wing formation. 
Plasmid rescue was performed using genomic DNA isolated as described (see 
below).  1µg DNA was digested with EcoRI using standard restriction digest 
procedure.  Using EcoRI digestion should yield a fragment of DNA containing the 
antibiotic resistance gene along with immediately flanking genomic Drosophila DNA.  
Digests were purified using a DNA clean-up kit (Qiagen) before ligation of the 
resultant DNA with standard procedures.  Following transformation of the ligation into 
E. coli, colonies were selected and sequenced using a plasmid directed primers: 
Internal 3’ EP forward primer; ACTATTCCTTTCACTCGCAC, and External 3’ EP 
forward primer  ATATCGCTGTCTCACTCAGA. 
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Removal of one of the two UAS elements present in the EP construct was 
performed using cre-recombinase [136] expressing line to Cre/loxP site-specific 
recombination to yield a single-headed EP element .  
 
Generation of transgenic flies 
The Drosophila melanogaster orb2 short and long isoform cDNAs were 
obtained from the DGRC (AT03031 and LP05645) in the pOT2 and the pOT7a vectors 
respectively. The cDNAs were cloned into the pUAST (pCaSpeR3, contains hsp70 
TATA box) vector (Brand and Perrimon 1993) and correct orientation of the inserts 
was checked by restriction digest and sequencing.  A single colony of bacteria 
containing each cDNA was grown overnight in 200ml LB-Ampicillin medium at 37°C 
in a shaking incubator.  Plasmid DNA was extracted with the Qiagen plasmid maxi-kit 
according to the manufacturer’s protocol.  The prepared construct was sent to Duke 
University (see results section) for injection.  Animals produced from the injection 
procedure were received and separated out at the pharate stage to maximize virginity.  
Upon emergence, these flies of the G0 generation were crossed individually to 3 yw 
flies of the opposite sex, and the resulting F1 generation was screened for 
transformants.  Transformers were crossed to balancer stocks and standard mating 
schemes were used to genetically map the affected chromosome.  Transgenes on the X-
chromosome were balanced over the FM7 chromosome (In(1)FM7, y31d sc8waB), 
second chromosome insertions were balanced over the CyO chromosome (In(2LR)O, 
Cy dplvI pr cn2),  and transgenes on the third chromosome were kept over either the 
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TM3sb (In(3LR)TM3, ri pp sep l(3)89 Aa bx34e e sb), or the TM6B (In(3LR)TM6B, Hu 
e Tb) balancer (Lindsley and Zimm 1992). 
 
Extraction from Drosophila tissues 
Heads and bodies, separated: 20-30 flies per genotype were isolated, and placed 
into an eppendorf tube with a needle puncture in the lid, and flash frozen in liquid 
nitrogen.  After removal from the nitrogen, the tube was rapidly and aggressively 
shaken for five seconds.  The contents were emptied into glass dish chilled over ice, 
where the still- frozen heads and bodies were separated from other tissues using a fine 
point paintbrush, and placed into a new eppendorf tube, and replaced in the liquid 
nitrogen.  Samples were processed for protein extraction immediately after removal 
from liquid nitrogen, by maceration with an eppendorf-sized pestle in 60-80µl of 
extraction buffer (as above), and followed by centrifugation at 14000XG for 20 
minutes at 4°C.  Supernatants were transferred to a fresh eppendorf tube and flash 
frozen in liquid nitrogen before storage at -80°C.   
Larvae/pupae/total adult: staged larvae/pupae/total adult were extracted in 10 
animals/100µl buffer by maceration with an eppendorf-sized pestle extraction buffer 
(as above), followed by centrifugation at 14000XG for 20 minutes at 4°C.  
Supernatants were transferred to a fresh eppendorf tube and flash frozen in liquid 
nitrogen  
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Extraction of Genomic DNA from flies 
For each genotype, 50 anesthetized flies were transferred to a 1.5ml eppendorf 
tube on ice and 250µl DNA isolation buffer (100mM Tris-HCl pH9.0, 100mM EDTA, 
1% SDS) was added.  Flies were crushed in the buffer using a plastic eppendorf pestle.  
One fiftieth volume of Proteinase K (10mg/ml) was added to the tube, and the extract 
was incubated for 30 minutes at 65°C.  An equal volume of ice-cold K-acetate (3M K-
acetate, 8.7% glacial acetic acid (v/v) was added and the mix incubated on ice for 30 
minutes.  Cell debris and precipitated proteins were removed by two subsequent 
centrifugation steps at 12000g for 5 minutes at 4°C.  The supernatant was transferred to 
a new tube and one half volume isopropyl alcohol was added, and kept at room 
temperature for 20 minutes.  DNA was pelleted by centrifugation at 12000g for 5 
minutes, and the pellet was washed with 1ml 70% ethanol.  The pellet was dried on the 
bench top, and resuspended in 25µl TE (Tris- EDTA buffer; 10mM Tris, 1mM EDTA, 
pH8) at room temperature for three hours.  DNA was extracted with half volume of 
phenol, and half volume of chloroform/isoamylalcohol, and finally with 
chloroform/isoamylalcohol.  DNA was precipitated with 2.5 volumes of 95% ethanol, 
and incubated overnight at -20°C.  The DNA was pelleted by centrifugation at 12000g 
for 5 minutes, washed with 1ml iced 70% ethanol, and dried on the bench.  DNA was 
resuspended in 50µ TE at room temperature overnight, and then stored at -20°C. 
 
Orb2 sequencing primers; 
CPEBLseq1:   AGAAAGTGTTGGTGCGGGCG 
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CPEBLseq2:   AGTGGCGGCGGAGATGCCTC 
CPEBsseq1:   GATTGTGAGTGTCCGTAAAA 
CPEBLseqU1: CCCACAGCTATCTATGGCAA 
CPEBLseqU2: CTTAAATGCCCTCAAAATGG 
CPEBLseqU3: ACCATGTCACTGGACCCACG 
CPEBLseqU4: GACGCGAATATCACAAGCCG 
These primers were used for sequencing the exact EP insertion, and for checking the 
pUAST constructs of orb2-PA and orb2-PB. 
 
Photography and Figure preparation 
Material used for preparation of flies; a Nikon Coolpix 995 digital camera 
mounted to a Leica Binocular microscope.  Flies were either killed using ether, or 
temporarily anesthetized for photography. Scanning electron microscopy preparation: 
Flies were chilled at -20°C for 30 minutes until <5% viable.  Flies were then mounted 
onto a metal pedestal with a sticky carbon paper, and underwent a timed sputter of gold 
particles (65 seconds,40% setpoint) at a mTORR of 55-60.  
 
2.3 Mammalian Experiments 
HeLa cells, derived from an adenocarcinoma [137], were cultured in high 
glucose DMEM supplemented with 10% heat inactivated foetal bovine serum (65°C, 
30 minutes), and penicillin plus streptomycin (Fisher), in a standard mammalian cell 
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culture incubator.  siRNA was transfected into 6-well dishes at 300,000 cells per well,  
using oligofectamine (Invitrogen) as per the manufacturer’s protocol, using 1.5µl of 
20µM solution per well. 
Qiagen siRNAs; 
Hs_ITPKA_6_HP Validated siRNA (S100605507) 
Hs_ITPKA_5_HP Validated siRNA (S100605500) 
Hs_ITPKB_6_HP Validated siRNA (S102621927) 
Hs_ITPKB_5_HP Validated siRNA (S102621934) 
Extraction from mammalian cells 
Experiments were performed in 6 well dishes.  Following treatments, the dishes 
were immediately transferred to a metal plate on ice.  The experimental media was 
removed and cells washed twice with 1ml/ well iced PBS.  Extraction buffer (120mM 
NaCl, 50mM Tris-HCl, pH7.0, 20mM NaF, 1mM benzamidine, 1mM EDTA, 6mM 
EGTA, 15mM Na4P2O7⋅10H2O, 1% Ipegal, 30mM paranitrophenylphosphate, 30mM 
β-glycerolphosphate, 4µM pepstatin A, 100µM PMSF, 2X promega complete inhibitor, 
1x phosphatase inhibitors.) was added on top of cells (75µl/well for HeLa and T98G, 
100µl/well for HEK293 and N41), and cells were scraped down with a rubber 
policeman.  Extractions for western blot were briefly vortexed, frozen and stored at -
80°C, and centrifuged at 14000XG for 20 minutes to remove cell debris prior to protein 
determination and use.  Extracts for immunopreciptation were lysed by pipetting up 
and down, and cell debris was removed by centrifugation at 14000XG for 15 minutes 
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at 4°C.  Supernatants were transferred to a fresh eppendorf tube and flash frozen in 
liquid nitrogen before storage at -80°C.  
  
2.4 General methods 
Western blotting 
Gels were soaked briefly in transfer buffer (0.01M CAPS PH11, 15% 
Methanol) following SDS-PAGE.  The gel was then arranged on top of a nitrocellulose 
membrane on top of two sheets of whatman filter paper equilibrated in transfer buffer, 
set on top of a semi-dry transfer apparatus.  Two sheets of equilibrated whatman paper 
were placed on top, and the lid replaced.  Proteins were transferred to the nitrocellulose 
paper by passing a constant current of 70mA for two hours.  Membranes were removed 
from the apparatus, rinsed with water, and checked for successful transfer and loading 
by ponceau S stain.  Membranes were then blocked in PBS with 3% BSA and 0.1% 
tween 20 for 30 minutes at room temperature with agitation.  Primary antibodies were 
incubated in the blocking buffer at 4ºC overnight. (antibodies).  Following this 
incubation, the membranes were washed in PBS with 0.1% tween-20 for thirty 
minutes, with a buffer change every ten minutes.  The secondary antibody (HRP 
conjugated) was then applied in a 1% non-fat milk PBS with 0.1% tween-20, and 
incubated at room temperature with agitation for two hours.  Membranes were then 
washed in PBS-Tween-20 0.1% for 15 minutes with a buffer change every five 
minutes. A final wash was performed in PBS alone, before allowing membranes to 
completely dry on a kimwipe.  Once dry, membranes were incubated with ECL 
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solution for one minute, placed inside a purpose-cut sheet protector, and exposed to 
photographic film (Kodak BioMax). 
  
Antibodies and concentrations 
Anti-IP3KA; Santa Cruz, 1:1000 Anti-IP3KB; Santa Cruz, 1:1000 Anti-S6k T389; 
Cell Signaling Rabbit Monoclonal, 1:2000, Anti-dS6K 398; Cell Signaling, 1:1000 
Anti-dPKB505; Cell Signaling, 1:1000, Anti-tubulin; University of Iowa Hybridoma 
Bank, 1:5000, Anti-orb2; gift from E. Kandel, 1:2000, Anti-Phospho dS6; 
Phosphosolutions, 1:2000, Anti S6; Cell Signaling, 1:1000, Anti total S6K; [101]. 
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CHAPTER 3: OO18 RNA-BINDING PROTEIN 2 
 
3.1 Introduction 
Conservation and structure 
The Drosophila melanogaster oo18 RNA-binding protein (orb) protein was first 
described in 1992 as an RNA-binding protein [138] with potential for regulation of 
mRNA localization. Since then, a number of studies in a wide range of organisms has 
found a conserved family of similar proteins with a role in regulation of mRNA 
translation by direct binding to consensus sequences in the 3’ UTR of mRNAs [139-
142].  This family of genes is referred to as the Cytoplasmic Poly-adenylation Element 
Binding (CPEB) family of proteins, after the Xenopus and mammalian genes.  There 
are often two CPEB genes in invertebrates, whereas there are four present in mammals, 
and evidence suggests that in both cases there are at least two subfamilies of proteins, 
the CPEB1 group and the CPEB2-4 group [143].  CPEB family members are identified 
on the basis of two RNA-recognition motifs (RRMs) and a zinc-finger motif, which 
CPEB1 requires for the binding of a specific cis-acting element in the 3’UTR known as 
the Cytoplasmic Poly-adenylation Element (CPE) [144] (Fig. 4).  The CPE element has 
a consensus sequence of UUUUUAU, although several minor variations of this 
sequence exists [143].  Polyadenylation of dormant mRNAs, for example, Xenopus 
cyclin B1, is controlled by this cis-acting CPE together with the hexanucleotide 
AAUAAA, through associations with CPEB and the cleavage and polyadenylation 
 37 
 
Figure 4: Comparison of orb2 and mCPEB3  
Conserved domains are indicated 
.Adapted from “Two previously undescribed members of the mouse CPEB family of 
genes and their inducible expression in the principal cell layers of the hippocampus” 
Theis M, Si K, Kandel ER.  Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9602-7
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specificity factor (CPSF) respectively [145].  The translational activation or repression 
of eukaryotic mRNAs has been observed as regulated by dynamic changes in the 
length of their poly(A) tails. This phenomenon, which is widespread among metazoans, 
is particularly characteristic of early development where poly(A) addition is associated 
with translational stimulation and poly(A) removal is correlated with translational 
repression [146, 147].  The interactions involved between CPEB and other proteins 
know to be involved in this process are discussed below.   
CPEB proteins have been implicated in the control of localization and 
translation of select messenger RNAs such as alpha-CaMKII [148], cyclin B1 [149, 
150], and AMPA receptor GluR2 [151].  The D. melanogaster CPEB orb1 is widely 
studied for its role in oogenesis, and was discovered as a protein with importance in 
formation of the egg chamber and establishment of polarity by anteroposterior and 
dorsoventral patterning [152, 153], whereas orb2 has a newly identified role in long-
term courtship memory [154]. 
 
CPEB interactors and regulation 
Although CPEB is a proven translational regulator in several species, it 
interacts with other proteins forming complexes which appear to vary depending on the 
species.  The most well characterized interactor, Xenopus Maskin, has been shown to 
be an eIF4E-interacting protein, whose binding prevents recruitment of the 
translational machinery to bound mRNA (Fig. 5) [155].  The site on eIF4E that 
interacts with Maskin is the same as that which is normally occupied by ribosomal- 
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Figure 5: Translational control by Maskin and CPEB.   
CPEB associates with both CPE-containing mRNAs and Maskin. Maskin, in turn, 
interacts with the cap (7mG)-binding factor eIF4E. In this configuration, Maskin 
binding to eIF4E precludes eIF4G from binding eIF4E, thus, inhibiting translation. 
Following CPEB phosphorylation and polyadenylation, PABP binds the newly 
elongated poly(A) tail; PABP also binds eIF4G and helps it displace Maskin from 
eIF4E. Because eIF4G is indirectly associated with the 40S ribosomal subunit (not 
shown), translation initiation proceeds. For clarity, other polyadenylation and 
translation factors are omitted. 
Adapted from "CPEB: a life in translation" Joel D. Richter, Trends in Biochemical 
Sciences, Volume 32, Issue 6, June 2007, Pages 279-285 
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 subunit-associated eIF4G, whose interaction with the cap-bound eIF4E is necessary 
for cap-dependent translation (see general introduction) [110].  Thus, Maskin is 
functionally similar to the 4E-BPs, as an inhibitor of translation, which precludes the 
interaction of eIF4G and eIF4E.  Another Xenopus 4E-binding-protein, neuroguidin, 
has also been identified as an interactor of CPEB, demonstrating the ability of CPEB to 
interact with multiple inhibitory 4E-binding proteins [156].  Although an association 
with CPEB has not been demonstrated, human orthologues of Maskin exist, termed the 
Transforming Acidic Coiled-Coil (TACC) family of proteins, are suspected to play a 
role in oncogenesis [157].   The Drosophila homologue D-TACC is important for 
proper dynamics of spindle pole microtubules during cell [158] via TACC-family 
interaction with the Aurora-A kinase, an interaction which is highly conserved [159].   
During Xenopus oocyte maturation, progesterone induces the inactivation of 
glycogen synthase kinase 3, which in turn is necessary for the activation of Aurora A 
kinase,  a serine/threonine kinase which phosphorylates CPEB at serine 174 [160].  
This event enhances the interaction between CPEB and CPSF, which is thought to aid 
cleavage and polyadenylation specificity factor stably associate with a second 
important cis element, AAUAAA [156].  The scaffold protein Symplekin contacts 
CPEB and CPSF, and aids them in interacting with Gld2, a poly(A) polymerase.  This 
event is required for CPEB-mediated polyadenylation [161].  More recently, additional 
interactors have been identified that add further complexity to the mechanism of 
translational control by CPEBs.  It was previously thought that negative regulation of 
translation by CPEB was due to a repression of polyA tail elongation.  More recently, 
however, the poly(A)ribonuclease (PARN) has been discovered as important factor in 
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the de-adenylation of mRNAs bound to CPEB.  Both PARN and Gld2 are present in 
complex with CPEB, and because PARN is the more active of the two, the poly(A) tail 
is short. When oocytes mature, CPEB phosphorylation causes PARN to be expelled 
from the ribonucleoprotein complex, allowing Gld2 to elongate poly(A) by default 
[145].   
 
The role of CPEB in the Brain 
Chemical synapses are specialized junctions through which the cells of the 
nervous system signal to one another and to non-neuronal cells via neurotransmitters. 
These synapses allow the neurons of the central nervous system to form interconnected 
neural circuits, and provide the means through which the nervous system connects to 
and controls the other systems of the body.  Synapses are asymmetric both in structure 
and in operation.  Presynaptic neurons secrete neurotransmitter, which binds to 
receptors facing into the synapse on the postsynaptic cell [162].  
‘Neuronal plasticity’ is the term used to describe the specialized structural and 
physiological events orchestrated by the nervous system to mediate the adaptive 
response of the organism to environmental changes or changes in the organism itself.  
Part of this plasticity is localized to synapses, and is dependent on the capability of 
synapses to modify their function, to be replaced, and to increase or decrease in number 
when required.  Neuronal plasticity is maximal during development and is expressed 
after maturity in response to external or internal perturbations, such as changes in 
hormonal levels, environmental modification, and injury [163].  The giant sea slug, 
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Aplysia californica is used extensively for research into synaptic plasticity, as it is an 
organism with a simple nervous system, consisting of just a few thousand large, easily-
identified neurons which are straightforwardly visualized in vivo, and is capable of a 
variety of learning tasks.  It has been shown that growth factors, such as transforming 
growth factor β (TGF- β) can enhance synaptic communication which is associated 
with plasticity [164].  While short-term changes in synaptic efficacy probably involve 
only posttranslational modifications, long-term changes require protein synthesis. For 
example, the production of new proteins is necessary for the acquisition of long-term 
memory, and for the long-lasting phases of hippocampal long-term potentiation (L-
LTP) in mammals, and long-term facilitation (LTF) in Aplysia.  During LTP the 
strength of synapses between neurons in the central nervous system is potentiated for 
prolonged periods following brief but intense synaptic activation, and there is 
correlative evidence that the mechanisms behind LTP are the same as those responsible 
for learning and memory.  In Aplysia and some other invertebrate synapses, this is 
referred to as LTF.  The converse mechanism to LTP is long term depression (LTD).  
Once synapses are potentiated, the level of synaptic efficacy can be reversed by 
prolonged low-frequency stimulation in a process known as depotentiation [165].  Both 
LTP and LTD are implicated in learning and memory processes [166].   
The CPEB family has been identified from Aplysia nervous tissue [167], and its 
role in the selective translation of mRNAs during L-LTP and LTF has since been 
investigated by several laboratories [167-169].  Work by Kandel’s group has 
demonstrated that a neuron-specific isoform of apCPEB (similar to the CPEB 2-4 
family) regulates LTF-associated growth [169].  It appears that apCPEB is required not 
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for the initiation, but for the stable maintenance of LTF.  Interestingly, the TOR 
signaling pathway has been implicated in translation-dependent L-LTP in the rat 
hippocampus, where several components of the pathway (mTOR, eukaryotic initiation 
factor-4E-binding proteins 1 and 2, and eukaryotic initiation factor-4E) can be detected 
[170, 171].  Kandel’s laboratory showed that the CPEB-dependent translation they 
witnessed during LTF was rapamycin sensitive [169]. They also discovered that 
apCPEB, has prion-like properties, meaning it has the unusual capacity to fold into two 
functionally distinct conformations, one of which is self-perpetuating. The cellular 
prion protein PrPc is a glycosylphosphatidylinositol-anchored cell-surface protein 
whose biological function is unclear, but some studies indicate that it may have a role 
in signal transduction [172].  When yeast prion proteins switch state, they produce 
heritable phenotypes. A high glutamine content and predicted conformational 
flexibility are observed in N-terminal portion of the neuron-specific apCPEB, which is 
most similar in structure to orb2 in Drosophila.  Kandel and his colleagues suggest that 
conversion of CPEB to a prion-like state in stimulated synapses helps to maintain long-
term synaptic changes associated with memory storage [173]. 
Recently, the role of Orb2 in long-term behavioral memory has been 
investigated by Keleman et al. using a male-courtship behavioral readout [154]. 
Courtship conditioning is thought to be a form of associative learning, involving male 
response to female pheromones [174, 175].  While the CPEB1 knockout mice have 
defects in memory extinction, they have no obvious phenotype associated with long-
term memory [176].  Orb2, on the other hand, is required for long-term behavioral 
memory, and is dispensable for learning and short-term memory [154].   Keleman et al 
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suggest that Orb2 is a regulator of component of the “synaptic tag”, an event postulated 
to mark specific synapses for the protein synthesis-dependent changes underlying long-
term behavioral memory. 
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3.2 Results: orb2 
The Drosophila orb2 gene effects S6K signaling. 
The Drosophila S6 kinase gene (dS6K) is a known regulator of organismal and 
cellular growth [101].  While the small size of tissues and cells lacking dS6K can be 
scored for, over-expression of the gene using the UAS GAL4 system in vivo has a 
much more subtle effect on growth. Apterous-GAL4 can drive expression of UAS 
target genes specifically in the dorsal wing compartment during development, and in 
the case of UAS dS6K over-expression, the resulting difference in size between dorsal 
and ventral compartments leads to a bent-down wing phenotype (see “Introduction”).  
This phenotype has been used as a readout for enhancers of dS6K mediated growth  
[85].    
From an Enhancer-Promoter (EP) screen outlined in Montagne et al (Appendix 
I), 57 lines containing randomly inserted ‘double-headed’ EP elements giving a clear 
enhancement of the dS6K induced bent-down wing phenotype were retained, and 45 
were molecularly mapped.  Males from balanced EP lines were crossed at a constant 
temperature of 25 ºC with double-transgenic female flies containing enhancer-trapped 
apterous-GAL4 (ap-GAL4) on the second chromosome recombined with UAS dS6K, 
and screened for modification of the previously observed bent down wing phenotype.  
Because so many EP insertions affecting a modification of this phenotype were 
isolated, a secondary screen was performed to compare their effects with the active 
S6K1dE/D3E (Montagne et al., Appendix I).   The subset of lines that displayed a weaker 
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effect with S6K1dE/D3E than by combination with dS6K were considered more likely to 
be involved with dS6K signaling, as this was the effect observed with co-over-
expression of DPDK1, a known effector of the pathway [95].  This differential 
phenotypic interaction may be a hallmark of specificity, as dS6K, unlike S6K1dE/D3E, is 
the genuine target for DPDK1 (Montagne et al., Appendix I).   
One of these lines, EP24.061, was found to be a strong enhancer of dS6K 
mediated growth, and produced a mild effect on its own when driven with the ap-
GAL4 driver (Fig. 6).  The genomic region of insertion EP24.061 was discovered by 
plasmid rescue as described [97].  After identification of the insertion cytological 
region 66E5, this location was verified by sequencing of EP24.061 homozygous males.  
This insertion was found to be located in the second intron of the gene oo18 RNA-
binding protein 2 (orb2).  The genes in the immediate vicinity in either direction of the 
insertion included the Gram-negative bacteria binding protein 3 (GNBP3), and the 
mitochondrial ribosomal protein L12 (mRpL12).  Because the mobilized EP element 
from the screen contained two independent UAS sequences for GAL4 to bind to in 
opposing directions, loxP sites were included to allow removal of one site, thus 
narrowing the search for the most likely gene involved .  The UAS sites at the 5' end of 
EP24.061 were excised by crossing the line with a cre-recombinase-expressing lines. 
Cre-loxP-mediated recombination yielded flies containing a single-headed EP element, 
removing the UAS sequence in a position capable of driving genes GNBP3 and 
mRpL12. Upon removal of this UAS sequence, the ap-GAL4 phenotype persisted, 
indicating that this phenotype was caused by either an overexpressed gene product of  
 47 
 
Figure 6:  Modification of a dS6K induced growth phenotype by an EP insertion 
in the drosophila dorsal wing blade.   
ap-GAL4 was combined the following genotypes; (a) yw (b) UAS dS6K (c) EP 24.061 
(d) UAS dS6K; EP24.061, and reared at 25 ºC.   The dS6K transgene resulted in a bent 
down wing phenotype, enhanced by the EP 24.061. 
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the orb2 gene, or a disruptive influence of the insertion on the orb2 gene or one of its 
close neighbors.  To determine which gene was responsible, we made two pUAST  
[177] constructs bearing cDNA variants of orb2.  The annotated gene from flybase 
[178] has 4 annotated transcripts (named -RA, -RB, -RC and -RD) and 4 corresponding 
polypeptides (-PA, -PB, -PC, -PD), three of which are identical.  This essentially 
results in two differential forms of the protein; orb2-PA which has a polypeptide of 551 
amino acids, and orb2-PB (and the identical -PC and -PD) with a polypeptide of 704 
amino acids (Fig. 7).  We obtained two clones from the Drosophila Genomics Resource 
Center (DGRC), the verified ‘DGC gold clone’ LP05645 (pOT2 vector) from the 
transcript orb2-RB, and AT03031(pOTB7 vector), which had a 5’ sequencing data file 
showing full sequence homology with the 5’ UTR from transcript orb2-RA.  To 
determine if AT03031 was indeed a full-length clone of orb2-RA, we performed a PCR 
using primers corresponding to 5’ and 3’ of the expected coding sequence of the orb2-
PA reading frame. After obtaining a product of the expected size, the amplicon was 
sequenced and found to indeed contain the coding sequence for  orb2-PA.  Both clones 
were digested out of their original vectors and directionally cloned into the pUAST 
vector using XhoI and EcoRI, present only in the multiple cloning site of the plasmids.  
The resulting constructs, pUAST orb2-PA and pUAST orb2-PB were purified and 
injected into Drosophila melanogaster w1118 embryos by Model System Genomics at 
Duke University [179].  Post-injection larvae were received from Model System 
Genomics and separated, survivors backcrossed with a yw- line, and their progeny 
screened for transformants.  Eight and eleven independent lines were obtained for UAS 
orb2-PA and UAS orb2-PB respectively, and these were balanced into stable lines.   
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Figure 7: orb2 transcripts and proteins, and position of EP24.061 insertion.   
Four mRNAs exist encoding two proteins, designated by Flybase as follows; RA, RB, 
RC, RD.  RB, RC and RD encode a 704 amino acid protein (from here referred to as 
orb2-PB) and RA encodes a truncated version at 551 amino acids (from here referred to 
as orb2-PA). 
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UAS orb2-PA and UAS orb2-PB transgenics were then crossed into the original 
ap-GAL4, UAS dS6K setting from the screen to test whether the enhancement on the  
bent-down wing phenotype originally observed with EP24.061 could be reproduced 
with either of the orb2 isoforms.  Unfortunately, the result was unclear for many of the 
lines because of lethality, possibly be due to the nature of the endogenous expression 
pattern of apterous, present not only in the dorsal wing compartment, but also in the 
nerve cords, eyes, olfactory organs, and brain [180].  Several of the lines for UAS 
orb2-PB did yield survivors (lines CL3, CL5, CL6), which surprisingly had a 
phenotype the opposite to the expected; a bent-up wing (Fig. 8).  This phenotype was 
present to the same extent whether the UAS dS6K transgene was present or not, and 
was observed in more than one independent line.  The natural properties of the yeast 
GAL4 transcription factor make it partially temperature sensitive [181], with the 
Drosophila window of use ranging from the less active 18 ºC to the more active 29 ºC, 
which is closer to the yeast’s natural optimum temperature.  This allows some 
manipulation of expression of UAS transgenes through raising or lowering the 
environmental temperature.  Therefore, we decided to test the effect of reducing the 
experimental temperature from 25 ºC to 18 ºC on the bent up wing phenotype of the 
UAS orb2-PB lines.  The resulting flies phenocopied those of the EP24.061 insertion 
from the screen, both in the presence and absence of the UAS S6K transgene (Fig. 9).  
Following this result, we were confident that orb2 gene product was responsible for the 
enhancement of the ap-GAL4 induced S6K phenotype observed with EP24.061.  The 
UAS-orb2-PA transgenic lines produced very few surviving flies when combined with  
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Figure 8: UAS orb2-PB suppresses a dS6K-induced growth phenotype in the 
drosophila wing.  
Apterous GAL4-expressing flies combined with (a) yw (b) UAS dS6K (c) EP24.061 
(d) UAS dS6K; EP24.061 (e) UAS orb2-PB (f) UAS dS6K; UAS orb2-PB  at 25 ºC   
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Figure 9: UAS orb2-PB enhances a dS6K-induced growth phenotype in the 
drosophila wing.    
Apterous GAL4-expressing flies were combined with (a) yw (b) UAS dS6K (c) UAS 
orb2-PB (d) UAS dS6K; UAS orb2-PB at 18 ºC. 
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ap-GAL4 or ap-GAL4, UASdS6K.  The survivors had deformed wings, with signs of 
extensive necrosis, which improved enough with decreased experimental temperature 
to detect an extreme curling up of the wing.  However, the necrosis was too advanced 
to draw conclusions about the effect of orb2-PA. 
 
orb2-PB over-expression does not rescue a TSC1&2 or PTEN growth defect 
Drosophila S6K resides downstream of dTOR complex 1, in a nutrient pathway 
parallel to the insulin-signaling TOR complex 2 pathway [85, 94].  These pathways are 
linked by a negative feedback loop, and although dPKB activity is not required for 
dS6K signaling in vivo [85, 182], cross talk between the two has been shown in cell 
culture [183]. The ectopic over-expression of tumor suppressors TSC1&2 and PTEN 
using the eyeless-GAL4 (ey-GAL4) driver results in a small-eye phenotype [184, 185].  
The rescue of either of these phenotypes by co-over-expression of a candidate gene 
could be indicative of a role in the nutrient-responsive dS6K arm (TSC1&2) or the 
insulin receptor-mediated dPKB arm (PTEN) of the pathway (Montagne et al., 
Appendix I).  Unknown elements can therefore be tested in this manner to discern 
which arm they belong to.  Given that the over-expression of orb2-PB not only 
enhances dS6K mediated growth (see above), but also produces a growth phenotype by 
its mis-expression alone, we decided to test it in this system.  Combinations of UAS 
TSC1, UAS TSC2 and UAS PTEN were established with either the EP24.061, or UAS 
orb2-PB (line CL6), and crossed with ey-GAL4.  The eyeless-induced over-expression 
of UAS TSC1&2 and UAS PTEN affected a small-eye phenotype as expected [184, 
185].  The combination of either the EP24.061 or the UAS orb2-PB with these  
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transgenes did not result in a rescue (Fig. 10); indicating that orb2 over-expression is 
unable to compensate for the phenotype provided by tumor suppressors in either arm of 
the pathway.  This experiment was also repeated at a lower temperature (18 ºC), with 
the same result (data not shown). 
 
Over-expression of orb2 in the eye suppresses growth and dS6K signaling 
One observation resulting from the eyeless-GAL4 experiment outlined above 
was that the eye size of eyeless-GAL4; UAS orb2-PB flies appeared to be reduced.  To 
gain a better understanding of the underlying cause of the size defects observed both in 
this system and also hinted at earlier in the wing, the eyeless-GAL4;UAS orb2-PB and 
GAL4;UAS orb2-PA flies were prepared for scanning electron microscopy along with 
controls (as described in “materials and methods” section).  Images were recorded of 
the flies at 180x and 1000x magnification (Fig 11, a-f), and later assessed for number 
of ommatidia and size of ommatidia (using Image J to quantify a pixels per ommatidia 
value).  Changes in both size and number of ommatidia were observed (Fig 11 g, h).  
 The UAS orb2-PA over-expression decreased the number of ommatidia 
reflected in compensation of ommatidial size.  UAS orb2-PB had no effect on the 
number of ommatidia, but did appear to reduce the size. These differences were 
statistically significant using an unpaired two-tailed t-test, with p-values of <0.01 in 
each case.  We concluded that the reduced eye size observed in this and the previous 
experiment was significant, and due to two different underlying reasons for each 
construct; fewer ommatidia for orb2-PA and smaller ommatidia for orb2-PB. 
 55 
f 
Figure 10: orb2-PB over-expression does not rescue TSC1&2 or PTEN induced 
small eye phenotype.   
Eyeless-GAL4 was combined with the following genotypes: (a)yw (b) UAS 
TSC1, UAS TSC2 (c) UAS PTEN (d) UAS orb2-PB (e) UAS TSC1, UAS TSC2; UAS 
orb2-PB (f) UAS PTEN; UAS orb2-PB (g) EP24.061 (h) UAS TSC1, UAS TSC2; 
EP24.061 (I) UAS PTEN; EP24.061.   
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Figure 11: Eyeless over-expression of orb2 induces ommatidial number and size 
defects. 
Eyeless GAL4-expressing flies were combined with (a) yw (b) UAS orb2-PA (c) UAS 
orb2-PB, and pictures were recorded at x180 magnification and for the same genotypes 
at x1000; (d)yw (e) UAS orb2-PA (f) UAS orb2-PB (g).  These effects on number (g) 
and size (h) of ommatidia are quantified in the charts, with ** denoting p<0.01 
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To gain a better understanding of the signaling involved in the growth phenotypes 
observed to this point, heads from 1-day-old flies overexpressing UAS orb-PA and -
PB, as well as over-expression from EP24.061 were removed and extracted for 
proteins.  Using an antibody raised against orb2-RA [169] (gift from Eric Kandel), we 
were able to visualize all forms of the overexpressed orb2 proteins, and indeed orb2-
PB was found to run at the same molecular weight as both the induced EP24.061 and 
what appears to be an endogenous band, ~70 kDa (Fig. 12).  UAS orb2-PA ran faster, 
and indicated a lower molecular weight of ~60 kDa.  Next, we used two phospho-
specific antibodies raised against phosphorylated dS6K T398 and dPKB S505 
(analogous to mammalian S6K T389 and PKB S473 respectively) to check if signaling 
was intact in these animals.  We found that over-expression of EP24.061 showed a 
slight and variable effect on dS6K phosphorylation, while UAS orb2-PA and -PB 
strongly suppressed the native phosphorylation status of dS6K.  dPKB appeared largely 
unaffected, suggesting that this effect was restricted to the dS6K arm of the pathway. 
With this knowledge, we attempted to rescue the more obvious growth defects 
caused by the eyeless induced orb2-PA induction.  We employed co-over-expression of 
UAS orb2-PA with UAS dS6K, since increasing expression levels of dS6K alone can 
increase the amount of phosphorylated dS6K present (Appendix II).  This co-over-
expression had no effect on the phenotype of the flies (Fig. 13), indicating that the 
small eye phenotype observed is not due to the reduced capacity for dS6K signaling; 
that the increased levels of dS6K was insufficient to maintain activity; or that the orb2 
effect is simply dominant to dS6K over-expression.   
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Figure 12: Over-expression of orb2-PA and orb2-PB with eyeless-GAL4 
suppresses dS6K phosphorylation at T389, but not dPKB S505 in Drosophila 
heads. 
All experiments shown are in presence of eyeless gal4.  (a) Over-expression of either -
PA or -PB form of orb2 reduces a signal as visualized by a phospho-specific dS6K 
antibody.  This effect is reproduced by several independent lines, whereas no 
consistent significant effect occurs by detection with dPKB phospho-specific antibody. 
(b) The reduction in phosphorylation status of dS6K is not due to a reduction of protein 
levels, since expression of dS6K is not affected.  Orb2 -PA and -PB isoforms can be 
differentiated based on size, with the -PA (shorter) form running just lower than the -
PB form, which runs around 70 kDa. 
PB 
PA 
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Figure 13:  Over-expression of dS6K does not rescue an orb2-PA induced small 
eye phenotype.   
Eyeless-GAL4 females were crossed to males of the following genotype; (a) yw (b) 
UAS orb2-PA (c) UAS dS6K (d) UAS dS6K; UAS orb2-PA.  Males shown 
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Since there is a defined component of this pathway which is known to give 
increased activity of dS6K by over-expression alone; the small GTPase Rheb [81], we 
decided to examine the effect of orb2-PA co-over-expression with this protein.  We 
 tested the EP Rheb line by using the eyeless-GAL4 system in order to allow 
comparison with our previous experiments.  Since over-expression of Rheb with this 
driver gave ambiguous results in terms of eye size we employed the published 
phenotype observed with GMR-GAL4.  The EP Rheb insertion driven by GMR-GAL4 
resulted in flies with increased eye size, ommatidial bulging, roughness, and sensory 
hair irregularities.  GMR-GAL4; UAS orb2-PB also generated a rough eye, with 
apparently elongated and often duplicated sensory hairs and bulging ommatidia, but 
without an increase in overall eye size.  The combinatorial effect of these two 
transgenes by GMR over-expression was increased roughness of the eye, without a 
clear effect on the size of the eye (Fig 14). 
 
Ubiquitous over-expression of orb2 suppresses growth and dS6K signaling 
The data above hinted at a role for orb2 as a suppressor of growth in certain 
conditions.  Although the fly heads developed smaller eyes following developmental 
expression of orb2 isoforms, and the apterous GAL4 driven over-expression bent the 
wings up in some circumstances, this was potentially indicative of some other 
phenomenon, such as loss of cell number by apoptosis.  To address this question of 
lethality at the level of the organism, we used ubiquitous drivers daughterless-GAL4 
(da-GAL4) and actin-GAL4 (act-GAL4) to test the viability of the flies.  Over- 
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Figure 14: Modification of a GMR-Gal4 -EP Rheb-induced growth phenotype in 
the eye by co-over-expression of UAS orb2-PB. 
GMR Gal4-expressing flies were combined with (a) yw (b) EP Rheb (c) UAS orb2-PB 
(d) UAS orb2-PB; EP Rheb. Females shown 
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 expression of all orb2-PA lines proved to be embryonic lethal with both of these 
drivers.  Several of the orb2-PB lines, however, produced adult emergers, albeit fewer 
than expected for wild type.  The majority of resulting flies were female with a small 
minority of male survivors (Fig. 15 a).  Pupae from the experimental tubes were 
compared for size, and it was found that those overexpressing orb2-PB were smaller 
than their wild type counterparts (Fig. 15b).  The fact that functioning adult flies could 
emerge from these smaller sized pupae adds credence to the notion that the previous 
size-related effects were not simply due to cell-lethality. 
Western blot analysis of wild-type and homozygous EP24.061 adults showed 
that, in general, female flies of both genotypes expressed higher levels of dS6K, and 
that EP24.061 homozygous females had increased phosphorylation of both dS6K and 
dS6 (Fig. 16).  Interestingly, when induced with the actin-GAL4 driver, EP24.061 and 
UAS orb2-PB (line CL5) females had reduced levels of dS6K T398 phosphorylation 
compared to the controls, suggesting that the EP insertion itself may have an effect on 
orb2 endogenous levels.   
 
Ectopic dFMR1 driven by ap-GAL4 phenocopies the induced orb2 bent up wing 
There is evidence for the binding and translational inhibition of Orb by the 
Drosophila Fragile X Mental Retardation (dFMR1) protein [186].  This information 
compelled us to test an EP insertion in dFMR1 (Bloomington) in the ap-GAL4 over-
expression system.  This EP, either alone or in concert with UAS dS6K produced a 
bent up wing (Fig. 17).  This was a clear indication that the bent up wing can be  
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Figure 15: Size and viability defects of orb2-PA and orb2-PB over-expression.   
The daughterless-GAL4 driver was used to induce expression of target genes.  
Top panel (A) shows percentages of unbalanced flies progressing to adult by 
comparison to their in-tube balancer control.  An expected Mendelian value is also 
shown for reference, and total is 50% due to selection of correct markers.   The lower 
panel (B) shows size defects in pupae overexpressing orb2-PB by daughterless-GAL4 
combined with  EP24.061 (b) or UAS orb2-PB (c) compared to yw; da-GAL4.  
genotype 
Percentage 
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Figure 16: orb2 expression effects dS6K signaling. 
In this figure ‘EP’ refers to the EP24.061 line, and ‘PB’ refers to the UAS orb2-PB 
line.  (A) Extraction of protein from adult heads reveals a reduction of orb2 expression 
in female flies homozygous for the EP24.061 insertion. (B) Total protein extracts from 
adult flies, shows female flies homozygous for the EP insertion have increase dS6K 
signaling.  Over-expression of orb2 by actin-GAL4 reduces dS6 phosphorylation in 
males.  dS6K null extracts shown as a control.  
(PB) 
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Figure 17: Over-expression of dFMR1 causes a suppression of growth phenotype. 
a) ap-GAL4, b) ap-GAL4, UAS dS6K, c) ap-GAL4; EP dFMR1 d) ap-GAL4, UAS 
dS6K; EP dFMR1.  Females shown.  
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produced by a retardation of growth by a known translational repressor, and that this 
inhibition is sufficient to overcome the enhancement of growth provided by over-
expression of dS6K.  
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3.3 Discussion 
Orb2 has a role in growth control 
The Drosophila-EP screen initiated by the laboratory was aimed at finding 
novel components of the dS6K pathway, using the subtle growth phenotype observed 
by the over-expression of dS6K to screen for modifiers.  Because so many EP 
insertions affecting a modification of this phenotype were isolated, a secondary screen 
was performed to compare their effects with the active S6K1dE/D3E (Montagne et al., 
Appendix I).   The subset of lines that displayed a weaker effect with S6K1dE/D3E than 
by combination with dS6K were considered more likely to be involved with dS6K 
signaling, as this was the effect observed with co-over-expression of DPDK1.  This 
differential phenotypic interaction may be a hallmark of specificity, as dS6K, unlike 
S6K1dE/D3E, is the genuine target for DPDK1 (Montagne et al., Appendix I).   
In the identification of the orb2 gene as an enhancer of the pathway, we appear 
to have also discovered a repressor.  Far from being a straightforward titration effect of 
the over-expression, it seems that the growth inhibition observed with increased levels 
of orb2-PB expression is due to a threshold effect.  Potentially, the level of orb2 protein 
required by the cell for efficient growth is fine-tuned, and once this level is overcome, 
effects become inhibitory.  This theory is supported by the fact that although both 
enhancement and repression of the dS6K-induced bent-down wing phenotype was 
observed, the effect was always an extreme modification of the phenotype; it never 
simply resulted in a straight wing, and the suppression of growth observed was always 
 68 
dominant to the dS6K bent-down wing phenotype (Fig. 6).  We also observed that 
over-expression with various other drivers consistently resulted in growth defects 
rather than enhancements (for example, eyeless-GAL4 resulted in smaller heads, and 
daughterless-GAL4 resulted in smaller pupae; Figs. 11 and 15), which could be a result 
of temporal or tissue-specific threshold effects, or promoter-related expression levels. 
The CPEB family of proteins first discovered in Drosophila by the Schedl 
laboratory [138] and soon after studied extensively by the Richter laboratory [187] has 
been shown to influence gametogenesis and early development, synaptic plasticity and 
cellular senescence through regulation of mRNA translation [143].  While CPEB1 has 
been implicated in the growth of mouse oocytes [188], and the role in control of 
translation and embryonic cell division of the CPEB family is clear from the literature 
mentioned above, a role in tissue or organismal growth has not yet been demonstrated.  
The overespression studies presented in this thesis strongly argue that orb2-PB can 
indeed enhance growth in the developing tissue of the wing imaginal disc, resulting in 
the ap-GAL4; UAS orb2-PB bent-down wing phenotype observed.   
The bent-up wing phenotype observed with the ap-GAL4; EP dFMR1 
experiment shows that this system can also be used to assess growth inhibition, since it 
is a known suppressor of tissue size (Fig. 17) [189].  With this knowledge, and 
knowing that lower levels of orb2-PB expression can enhance growth in this tissue, we 
hypothesize that the bent-up wing observed at higher temperatures is a clear indication 
that at a certain point, high levels of this protein become inhibitory.  
However, over-expression studies have the caveat that even when using wild-
type gene products, mis-expression can cause both “dominant-negative” type effects, 
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as well as artifactual ones.  As mentioned in the introduction, dPI3K function can be 
inhibited by over-expression of its adapter subunit, dp60 [90, 91].  If interacting 
proteins are required at equimolar amounts in the cell (or at specific ratios), disruption 
of this balance would possibly cause deleterious effects, opposing the endogenous role 
of the protein.  To ascertain the true role of this gene in vivo, a mutant must be 
generated.  In the case of orb2, this could be achieved by an imprecise excision by 
remobilization of the EP element in the 5’ UTR of the gene, leading to a disruption of 
the gene [190].  Alternatively, ethyl-methanesulfonate (EMS) mutagenesis of 
EP24.061 male flies, followed by a re-screening of the progeny with the ap-GAL4; 
UAS S6K flies could result in revertants, and help to identify a point mutation causing 
either a loss-of-function allele, or a null.  This has already proved a successful strategy 
for another EP candidate from the screen (Appendix I).  This would be a useful tool, 
because if a point mutation could be isolated occurring at a residue critical for function 
of the gene, it could be used for both loss-of-function and dominant negative over-
expression studies due to the EP insertion upstream.  
 
Orb2 over-expression produces large amounts of protein 
Using larval extracts with a one-hour recovery from heat-shock-GAL4 
induction of the transgenes (appendix III), we noticed that orb2 proteins accumulate 
very soon after induction.  This means that extracts observed in Figure 12 (b) are 
slightly misleading, because although only a moderate induction of the proteins was 
observed, we have noticed that it is difficult to visualize other overexpressed proteins 
using this driver (eye-GAL4), possibly due to the timing of expression compared to 
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extraction of proteins from adult heads.  One explanation for the strong induction of 
orb2 proteins is that they were cloned into the pUAST vector including the full-length 
3’UTR, which could potentially contain auto-regulatory sequences, as has been 
demonstrated with orb mRNA [191].  Although there does not appear to be the 
required hexanucleotide or classical CPE usually required for CPEB1 regulation 
(AAUAAA and UUUUAU respectively; see orb2 introduction and [192] for full 
explanation), the possibility remains that orb2 mRNA is translationally auto-regulated.  
For example, CPEB proteins 2–4 do not bind the CPE to the same extent as CPEB1 in 
mammals, but instead strongly interact with a U-rich loop within a stem–loop structure 
in the 3’ UTR of mRNAs [151].  Engineering a transgene containing only the coding 
sequence of the orb2-PB would be one way to circumnavigate this particular issue.   
In addition, since orb1 and orb2 are auto-regulated [186, 193], and Rapamycin 
blocks induction of the Aplysia homologue of CPEB3 [194], it would be interesting to 
see if this rapid accumulation of orb2 protein is rapamycin-sensitive, by performing the 
heat-shock experiment on larvae pre-fed with rapamycin. 
 
Raising orb2 to inhibitory levels reduces dS6K signaling 
The fact that the ap-GAL4;orb2-PB wings bent-upwards to the same extent 
whether overexpressed dS6K was present or not (Fig. 8), showed that the suppression 
of growth caused by orb-PB was dominant to dS6K mediated growth.  While ap-
GAL4; UAS orb2-PA flies were often lethal, or survived and had wing necrosis, we 
demonstrated that a suppression of growth in the eye caused by eye-GAL4; UAS orb2-
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PA could not be reversed with co-over-expression of dS6K (Fig. 13).  Following 
extraction of heads from the over-expression of orb2-PA and orb2-PB using the eyeless 
driver, it was clear that over-expression of orb2 could have an inhibitory effect on 
dS6K phosphorylation status (Fig 12).  As mentioned in the first section of this 
discussion, over-expression can produce deleterious side effects which are not 
necessarily representative of the proteins’ endogenous action.  However, the effect 
observed still indicated to us that orb2 is involved in the dS6K signaling pathway, 
because there was no effect on the phosphorylation status of dPKB.   
 
Sex-specific effects of orb2 and dS6K 
The original phenotype observed from the P-element insertion in the dS6K 
gene, later used to generate the published excision-mutant dS6Kl-1 [101] was observed 
to be female sterile, along with having some of the other traits of the excision mutant; 
partial lethality, a developmental delay, and reduced body size.  From western blots, a 
difference in total levels of dS6K can be seen between male and female flies (Fig 17).  
This difference does not appear to translate into a difference in activity of the kinase, as 
determined by anti dS6K-T398 and anti phospho- dS6 antibodies.  Indeed, the only 
evidence of a sex-specific increase of dS6K T398 phosphorylation is an increase in the 
homozygous EP insertion for orb2. Meanwhile, orb2 levels are reduced in the female 
flies homozygous for EP24.061 where this increase occurs (Fig. 17), while driving the 
EP or UAS orb2-PB with actin-GAL4 causes a reduction in T398 dS6K (and phospho-
dS6 in the case of orb2-PB), this would suggest that orb2 has a repressive effect on 
dS6K phosphorylation.  One possible explanation for this is that orb2 is a downstream 
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target of dTOR, rather than dS6K, and while a small amount of over-expression can 
enhance growth by orb2-mediated translation, larger doses can titrate out activity of 
dTOR towards dS6K and other substrates, resulting in growth inhibition (see below).  
TOR proteins interact with their substrates through conserved TOS motifs [51].  While 
no clear motif is present in orb2, it is possible that the interaction is though an 
alternative motif, or through a mediator.   
Interestingly, it is the homozygous EP24.061 males who appear to have a 
phenotype.  The EP24.061 retained the TM6b balancer with which it was originally 
maintained, despite the presence of homozygous viable flies in the tube.  When 
working with Drosophila lines, this is often an indication that the mutation on the 
balanced chromosome is either weak or infertile.  After setting several tubes of crosses, 
we discovered that homozygous males were sterile, while females were not.   Recently, 
the first paper on orb2 was published [154].  This study used homologous 
recombination to generate two targeted mutations of the gene, one a full deletion of the 
coding sequences (orb2Δ), and the other an in-frame deletion removing the conserved 
polyglutamine region in the N-terminus of the protein (orb2ΔQ), (refer to Fig. 4 for 
conserved region).  While orb2Δ was homozygous lethal, the orb2ΔQ homozygotes and 
orb2Δ/ orb2ΔQ trans-heterozygotes were viable with no gross morphological defects.  
Using a courtship-based memory assay, the authors found that long term, but not short 
term memory was impaired in these animals.  It is tempting to think, therefore, that the 
EP homozygous flies do indeed have a disruption of normal orb2 function, and this 
results in the homozygous sterility phenotype of the males.   
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In addition to the potential effect on fertility, when driving the EP insertion 
with the actin promoter, we found that phosphorylation of the dS6K substrate, dS6 was 
abolished by comparison to a yw- control specifically in males (Fig 17).  Driving any 
of the UAS orb2-PB lines with actin did not produce adult males, although driving with 
another ubiquitous driver, daughterless-GAL4, did produce a small number of male 
survivors (Fig 15, graph).  These data suggest that orb2 protein levels play an 
important role in the development of male flies.  
 
Relationship of orb2 and TSC1&2 
Taken against the backdrop of the ap-GAL4 enhancement of the UAS dS6K-
induced bent-down wing phenotype, our initial reaction to the eye-GAL4, UAS 
TSC1&2 and UAS PTEN experiments (Fig 10), where UAS orb2-PB did not rescue 
the small eye phenotype, was that orb2 is hypostatic to the TSC complex.  However, it 
was soon apparent that the action of UAS orb2 in this case was potentially different to 
the enhancement phenotype observed in the wing.  While over-expression of the tumor 
suppressor complex dTSC1&2 or dPTEN in the eye resulted in an obvious small-eye 
phenotype, over-expression of orb2-PB also reduced eye size, albeit in a much more 
subtle manner.  With this knowledge, the argument that dPTEN or dTSC1&2 are 
epistatic to orb2 is lost, since the over-expression may be inducing an inhibitory 
phenotype, as indicated in the above paragraphs. In the case of co-over-expression of 
UAS TSC1&2 and UAS orb2-PB, there was even what appeared to be an enhancement 
of the phenotype in approximately half the flies.  The eye-GAL4, UAS dTSC1&2 
phenotype has been attributed largely to cell cycle disruption, rescued by co-over-
 74 
expression of cyclins D or E, or dS6K [185] and since the CPEB proteins play an 
important role in the control of cell cycle [195], this could be a potential link between 
these genes.  However, unlike TSC, orb2-PA induced suppression of growth could not 
be rescued by over-expression of dS6K. This would argue that orb2 has a greater effect 
on the suppression of growth than merely inhibiting dS6K phosphorylation. There is a 
strong possibility that over-expression of orb2 could result in a phenotype stronger to 
that of the loss of orb2.  This hypothesis is based on CPEB3 in mammals, where whilst 
translation of certain messages are enhanced by its activation of CPEB3, the expression 
of these proteins is not completely suppressed upon loss of CPEB, and RNAi depletion 
of CPEB can even enhance the expression of these messages [151].   
 
Models of orb2 influence on dTOR/dS6K signaling 
Bearing in mind the above observations that orb2 can both enhance and 
suppress dS6K mediated growth, four possibilities stand out as theories for the action 
of orb2 on dS6K activity (Fig. 18); (1) orb2 is an upstream activator of dS6K, which, 
when overexpressed at high levels causes an inhibitory effect on the pathway through a 
“dominant negative” effect of mis-expression, potentially titrating out necessary 
upstream components. (2) orb2 regulates translation of an upstream component of the 
pathway, and over-expression or the component behaves as described in (1).   (3) orb2 
is a downstream target and binding partner of dS6K, and can interfere with its the 
normal localization, sequestering it from phosphorylation, or bring it into contact with 
a regulatory phosphatase.  Work from John Blenis [114] showed that mTOR and S6K1 
undergo dynamic interchange by interaction with the pre-initiation complex on mRNA,  
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Figure 18: Models of orb2 involvement in the dTOR/dS6K signaling pathway. 
See text for details  
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and since CPEB family members interact with eIF4E-binding proteins, it is a 
possibility that over-expression of orb2 interferes with this process. (4) orb2 is 
downstream target of dTOR, parallel to dS6K, and its over-expression titrates out TOR 
activity away from dS6K.  In this scenario, size defects observed by over-expression of 
orb2 could be due to high levels causing a reduction of phosphorylation of other 
substrates, such as dS6K.  This model is supported by work by Sonenberg’s group 
earlier this year, which showed that the double knockout mouse for 4E-BP1 and 4E-
BP2 showed an elevated sensitivity to diet-induced obesity and insulin resistance in 
mice [196].  This was an unexpected result, considering that the single knockout mice 
for 4E-BP1 had a lean phenotype [197].  The increased adiposity of the double 
knockout mice was concurrent with increased activity of S6K, and reduction of PKB 
activity, indicating that by removing one substrate of TOR, another may benefit [196].  
This indicates that an imbalance of signaling can be brought about by changing the 
levels of TOR substrate expression.  
 
Future work with orb2 
The potential interaction between dS6K or dTOR and orb2 is the most tempting 
of avenues to proceed with.  The next steps with this project should be heavily 
weighted towards identifying any interaction by direct association, or by 
phosphorylation. A potential S6K consensus motif exists in both the mammalian 
CPEB3 and 4 [194], and the drosophila orb2 (by analysis using MIT Scansite [198].  
Because mCPEB3 has been shown to regulate translation of GluR2, it would 
interesting to find out if GluR2 translation is also affected by Rapamycin, either in the 
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fly or in mammals.  dFMR1, the Drosophila Fragile X gene, has been shown to 
negatively regulate both orb and orb2 translation [186, 193].  The potential role of this 
gene in our orb2/S6K story is of great interest, since the role of both CPEB and FMR1 
is well documented in the brain, and area of widening research for TOR signaling.  In 
addition, imprecise excision crosses are currently being screened for a loss-of–function 
allele of orb2, following which, it will be possible to address the question of whether 
orb2 is essential for growth in drosophila, and if lethal (as expected from [154]), to 
check if any growth effects observed are  cell-autonomous events using clonal analysis. 
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CHAPTER 4: Inositol(1,4,5) Phosphate Kinase 1 
 
4.1 Introduction 
Inositides 
Crystallization of a novel carbohydrate compound, ‘inositol’ from muscle 
extracts more than one hundred and fifty years ago by the German chemist Josef 
Scherer[199] began what the widely studied field of inositol second messenger 
research.  The structural basis of the most naturally abundant form of this inositol (also 
known as ‘myo-inositol’) is a carbocyclic polyol where the 1st, 3rd, 4th, 5th and 6th 
hydroxyls are equatorial, while the 2nd hydroxyl group is axial.  As well as being 
readily available in many food sources, inositol is synthesized de novo from glucose in 
a number of organs, including brain, testis, kidney and liver[200]. The general term 
‘inositides’ refers to the group of cellular components whose commonality is the 
inclusion of myo-inositol as part of their chemical structure.  This group can be divided 
into two very different subgroups: insoluble inositol lipids that contain a phosphatidyl 
group, and the soluble inositol phosphates that do not. Inositol phospholipids are found 
concentrated at the cytosolic surface of membranes, after delivery of the precursor 
phosphatidylinositol (PI) by vesicular transport or specialized transfer proteins from 
the major site of synthesis, the endoplasmic reticulum.   Reversible phosphorylation of 
positions 3, 4, or 5 of the inositol ring in various combinations gives rise to several 
species of phosphoinositide with different signaling capabilities, such as 
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phosphatidylinositol-4,5-bisphosphate (PIP2), which is both a precursor of intracellular 
messengers generated by phospholipases and also a direct signaling molecule [201].  
Phospholipase C (PLC) induced PIP2 cleavage as a result of  agonist occupation of cell 
surface receptors generates a second type of inositide, in this case specifically inositol 
(1,4,5)-phosphate (IP3), which can be metabolized into various other forms of inositol 
phosphate [202, 203].  In the same reaction, diacylglycerol is produced, which is also a 
second messenger, and provides positive feedback stimulation of PLC to amplify 
agonist-induced Ca2+ signaling in response to weak extracellular stimuli  [204].  Very 
little is known about the higher inositol phosphates such as Ins(1,3,4,5,6)P5 (IP5), 
Ins(1,2,3,4,5,6)P6 (IP6) and the diphosphoinositol polyphosphates, but it is thought that 
they could have extremely diverse roles in the cell, such as aiding efficient messenger 
RNA export [205], or acting as primary phosphate donors to acceptors other than ADP, 
such as proteins [206, 207]. 
 
Inositol signaling 
Activation of phosphoinositide-specific phospholipase C (PLC) generates an 
ensemble of intracellular inositol phosphate (IP) second messengers involved in diverse 
cellular processes [208]. Among these are IP3, which functions as a regulator of 
calcium release [209] and as a precursor to more highly phosphorylated IP molecules, 
including inositol (1,3,4,5)-phosphate (IP4), IP5, IP6, and inositol pyrophosphates (PP-
IPs) [210]. The PP-IPs have more phosphates than IP6 [211, 212], functional analyses 
of the IP6 kinase that produces such higher phosphates is required for maintaining 
cellular integrity, temperature-dependent growth, and rod-shape morphology in yeast 
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[208].  Work on IP3 and IP4 went hand in hand, following the discovery of inositols IP3 
[213] and IP4 [214] upon Carbachol stimulation of rat cortical slices and parotid gland 
fragments, when it was thought that IP4 could be the precursor.  Since then, it has been 
found that Ins(1,4,5)P3 3-kinase (IP3K), which converts IP3 to IP4, is the most active 
inositol phosphate kinase detectable in mammals, having a prominent role in rapidly 
metabolizing the pool of IP3 that is generated when phospholipase-C-coupled receptors 
are activated [215].  As a consequence of IP4 formation, IP3 is protected from 
dephosphorylation by 5-phosphate phosphatase [216]. Together, IP3 and IP4 aid in the 
mobilization of calcium within the cell.   
Inositol phosphates IP3 and IP4 regulate calcium mobilization via the inositol 3-
phosphate receptor (IP3R), of which there are three isoforms in mammals, and one in 
drosophila.  These intracellular calcium ion (Ca2+) channels that play a critical role in 
generating Ca2+ signals that accompany the stimulation of cells with many different 
types of agonists [217], and are regulated by Ca2+ and IP3 binding.  The IP3R exists 
physiologically as a tetramer and, despite some tissue specificity, there is evidence that 
it may exist as a heterotetramer [218].  The Ca2+ regulation of IP3 receptors is biphasic, 
the Ca2+ binding site which binds to two distinct sites, and IP3 promotes channel 
opening by controlling whether it binds to the stimulatory or inhibitory sites [219].   
When Ca2+ levels begin to rise, the ER-based IP3R channel is activated, in a positive 
feedback loop, which is known as ‘Ca2+ -induced Ca2+ -release’ (CICR).  At high levels 
of Ca2+ concentration, the channels close again, which is required for replenishment of 
the ER calcium stores.  This results in oscillating levels of Ca2+.  In addition, depletion 
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of ER-calcium stores can cause extracellular calcium influx, via the store-operated 
calcium channels [220].  
 
IP3K regulation 
Three different IP3K genes exist in mammals, IP3KA, B and C (sometimes 
referred to as ITPKA, B and C), and they differ in molecular mass, Ca2+/calmodulin 
sensitivity, intracellular distribution, and tissue expression [221, 222].   Many of the 
cellular effects of calcium ions are mediated by the Ca2+ binding protein, calmodulin 
(CaM).  Upon binding up to four ions, CaM undergoes a conformational change, which 
enables it to bind to specific proteins such as Calmodulin kinase II (CaMKII) and 
Calcineurin [223].  When bound by Ca2+/CaM, up to a 20-fold of increase in IP3Ks 
enzymatic activities can be observed in a in vitro assay using purified IP3Ks from rat.   
Calcium sensitivity of the slightly larger IP3KB isoform is greater that that of 
the IP3KA form, and rat IP3 kinase isoforms have been found to show a tissue-specific 
expression pattern, with RnIP3KA present in brain and testes, and RnIP3KB expressed 
predominantly in lung, thymus, heart, testes and brain [224].  Mammalian IP3Ks are 
substrates of cAMP-dependent kinase (PKA), protein kinase C (PKC) and 
Ca2+/CaMdenpendent kinase II (CaMKII). PKA can stimulate IP3K activity . In 
contrast, PKC is a negative regulator of IP3K by phosphorylation [225] at Ser-175 of 
rat IP33K-A.  Ser-109 serves as a site for both PKC and PKA, and while simultaneous 
phosphorylation of Ser-109 and Ser-175 leads to inactivation of the enzyme, a single 
phosphorylation at Ser-109 activates it, suggesting that Ser-175 is probably the 
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inhibitory phosphorylation site [226]. CaMKII is also a positive regulator of IP3K, by 
phosphorylation of Thr-311 on  human IP3KA, which stimulates enzyme activity by 
8~10-fold [225, 227]. 
There are several downstream consequences of IP3K activity (Fig. 19). A 
complete inhibition of IP3K activity in Hela cells by adriomycin (an IP3K inhibitor) or 
by an IP3K specific antibody blocked Ca2+ oscillations, whereas a partial inhibition 
caused a significant reduction in oscillation frequency [228].  Rat and human IP3Ks 
may be involved in brain development, as rat IP3K activity is low at birth (~50% of the 
adult expression), while spatial learning training leads to an increase of rat IP33K-A 
level [229, 230].  Meanwhile, ubiquitous over-expression of D-IP3K1, the Drosophila 
homologue of IP3KA, confers specific resistance to hydrogen peroxide induced 
oxidative stress, and the authors claim that the protective effect of D-IP3K1 is mainly 
due to reduced IP3 levels, and thus reduced calcium release from internal stores [231].   
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Figure 19: The network of IP3K functions. 
IP3Ks are involved in inositol signaling pathway, calcium signal transduction, brain 
development, stress responses and gene transcription.  They are activated by the 
Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) and protein kinase A (PKA).  
Evidence suggests that phosphorylation by protein kinase C (PKC) is inhibitory, 
although this is still debated.   
Adapted from “Inositol 1,4,5-trisphosphate 3-kinases: functions and regulations”, Xia 
HJ, Yang G. Cell Res. 2005 Feb;15(2):83-91 
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4.2 IP3K1 results 
IP3K1 enhances dS6K induced growth  
IP3K1 was identified as a candidate enhancer of dS6K mediated growth from 
the screen outlined in the previous chapter, where the bent-down wing phenotype of 
ap-GAL4, UAS dS6K was used to screen an EP collection in Drosophila for potential 
novel components of the pathway.  Because so many EP insertions affecting a 
modification of this phenotype were isolated, a secondary screen was performed to 
compare their effects with the active S6K1dE/D3E (Montagne et al., Appendix I).   The 
subset of lines that displayed a weaker effect with S6K1dE/D3E than by combination 
with dS6K were considered more likely to be involved with dS6K signaling, as this 
was the effect observed with co-over-expression of DPDK1.  This differential 
phenotypic interaction was used to identify enhancers similar to DPDK1, a proven 
upstream component of the pathway (Montagne et al., Appendix I and [85]).   
Fifty-seven lines containing randomly inserted ‘double-headed’ EP elements 
giving a clear enhancement of the dS6K induced bent-down wing phenotype were 
retained, and 45 were molecularly mapped using plasmid rescue.  Males from balanced 
EP lines were crossed at a constant temperature of 25ºC with double-transgenic female 
flies containing enhancer-trapped apterous-GAL4 (ap-GAL4) on the second 
chromosome recombined with UAS dS6K, and progeny were screened for 
enhancement of the bent-down wing phenotype.  One line, EP13.148, was found to be 
a moderate enhancer of dS6K-mediated growth, and had no effect on its own when 
driven with the ap-GAL4 driver (Fig. 20).  The genomic region of insertion EP13.148  
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Figure 20:  Modification of a dS6K induced growth phenotype by an EP insertion 
in the drosophila dorsal wing blade. 
ap-GAL4 was combined with the following genotypes.; (a) yw (b) UAS dS6K (c) 
EP13.148 (d) UAS dS6K; EP13.148 flies, and reared at 25 ºC.   The dS6K transgene 
resulted in a bent down wing phenotype, enhanced by the EP 13.148 insertion 
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was identified by plasmid rescue (Materials and Methods), located at cytological 
location 30C9.  This was found to just upstream of the first exon of the Inositol-1,4,5-
triphosphate kinase 1 (IP3K1) gene.  The other genes in the immediate vicinity of the 
insertion included the sodium transport activity genes pickpocket 11 and pickpocket 16.  
The EP element used in the screen contained two independent UAS sequences for 
GAL4 to bind to in opposing directions, but unfortunately, unlike the case with orb2, 
removal of one of these UAS sites was not possible.  This is because the first EP lines 
generated for the screens did not contain ‘LoxP’ sites, and hence could not be 
recombined in this manner.  Since the closest gene to the insertion was IP3K1, and two 
other published EP insertions in the immediate vicinity had been shown to drive over-
expression of this gene [231], we decided to first assess whether this gene could indeed 
be responsible for the effect.  The IP3K1 gene in Drosophila has only one described 
transcript and protein (IP3K1-RA and IP3K1-PA respectively), and will be referred to 
simply as IP3K1 (Fig. 21).  Fly lines containing a p(UAS)IP3K1 insert in the second 
and third chromosomes in a w1118 background [231] were provided by H. Tricoire 
(University of Paris, France).   
The UAS IP3K1 lines were introduced into the sensitized ap-GAL4, UAS 
dS6K system, and the resulting flies displayed a moderate enhancement of the bent-
down wing phenotype similar to that observed in the screen, with no effect on its own 
(Fig. 22).  This indicated that the result from the screen could be attributed to an over-
expression of IP3K1, rather than to disruption of the gene, or over-expression of either 
of the pickpocket genes.  
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Figure 21: IP3K1 locus and insertion point. 
The IP3K1gene has a single transcript and protein annotated in Flybase.  The EP13.148 
insertion point of the EP at 50 bp upstream of the first exon, and in-between two 
previously described EP insertions, and 8 Kb from the next closest gene, pickpocket11.  
The two UAS lines obtained from Hervé Tricoire contain the coding frame associated 
with IP3K1-RA, predicted to make a protein of around 50kDa. 
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Figure 22: Modification of a dS6K-induced growth phenotype in the wing by 
IP3K1 and an EP insertion in the IP3 Receptor (ITPR).   
ap-GAL4-expressing flies were combined with (a) yw (b) UAS dS6K (c) EP IP3K1 (d)  
EP IP3K1/ UAS dS6K (e) UAS IP3K1 (f) UAS dS6K; UAS IP3K1(g) EP IP3R, (h) 
UAS dS6K; EP IP3R at 25° C 
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 As mentioned earlier, manipulation of GAL4 expression by changing the 
ambient temperature is a characteristic of the UAS-GAL4 system.  Therefore, the level 
of IP3K1 gene expression was raised with increased temperature to test the dose-
responsiveness of the bent-down wing phenotype. The effect of increasing the 
experimental temperature from 25ºC to 29ºC was indeed an increase in the 
enhancement of the ap-GAL4, UAS dS6K bent-down wing phenotype by both the 
UAS IP3K and EP13.148 from the screen (Fig. 23).  This confirmed that over-
expression of IP3K1 was responsible for the enhancement of the ap-GAL4-induced 
S6K phenotype, and an indication that the enhancement was sensitive to levels of 
IP3K1 produced in the developing fly.   We also obtained a stock from Bloomington, 
which has an EP-element inserted in the 5’UTR of the IP3 Receptor gene (IP3R), to 
test in our system.  We were interested to see if another component of the same 
pathway could have an effect on dS6K-mediated growth.  The EP insertion in IP3R did 
also enhance the bent-down wing phenotype, but we do not know if this is due to a 
disruption of the IP3R gene, or over-expression, since successful visualization of a 
gene product has yet to be achieved. 
As a further confirmation, GMR-GAL4 was used to drive both the UAS IP3K 
and EP13.148 in the developing eye, and heads were removed for western blot 
analysis.  While no Drosophila-specific IP3K1 antibody is available, several antibodies 
raised against areas of strong homology with the human homologue, IP3KA, were 
tested using western blotting techniques as outlined in “Materials and Methods”.  One 
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Figure 23: Temperature modification of the IP3K1-enhanced dS6K-induced bent-
down wing phenotype. 
ap-GAL4-expressing flies were combined with (a) yw (b) UAS dS6K (c) EP IP3K1 (d)  
EP IP3K1/ UAS dS6K (e) UAS IP3K1 (f) UAS dS6K; UAS IP3K1 at 29°C. 
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 of these antibodies (anti-IP3KA, Santa Cruz) showed no signal in the yw; GMR-
GAL4 flies, but detected a protein of the approximate estimated molecular weight of 
IP3K1 (~50kDa) in both the GMR-induced UAS IP3K and EP13.148 (Fig. 24).  This 
implies that the antibody can detect Drosophila IP3K1 when overexpressed, but not at 
endogenous levels, and suggests that IP3K1 protein levels were responsible for the 
enhancement effect witnessed.  
 
IP3K1 rescues a TSC1&2 over-expression-induced phenotype 
The tumor suppressor complex containing TSC1 and TSC2 has been well 
studied in the Drosophila model.  Co-over-expression of TSC1&2 proteins using the 
eyeless promoter results in a retarded growth phenotype [184, 185].  Known 
components of the dS6K signaling pathway have been shown to rescue this phenotype 
[94].  To test if IP3K1 over-expression can help to overcome the growth suppression 
caused by this complex, we tested both the UAS and EP13.148.  We found that, in both 
cases, the small-eye phenotype was completely reverted by over-expression of IP3K1 
(Fig. 25).  This indicates that not only can IP3K1 enhance dS6K-induced growth, it can 
also compensate for upstream inhibition of the dS6K signaling pathway by a well-
defined negative effector.   
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Figure 24: Identification of IP3K1 gene product from fly heads. 
GMR-GAL4 was used to drive UAS IP3K1 from two independent lines, along with the 
EP13.148 (as annotated).  
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Figure 25: IP3K1 rescues a small eye phenotype induced by TSC1&2 over-
expression.  
Eyeless-GAL4 combined with (a) yw (b) EP13.148 (c) UAS IP3K1 (d) UAS TSC1, 
UAS TSC2 (e) EP13.148; UAS TSC1, UAS TSC2 (f) UAS TSC1, UAS TSC2; UAS 
IP3K1.  Males shown. 
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The mammalian IP3KA gene is implicated in the TOR/S6K signaling pathway 
Following the indication from Drosophila over-expression studies that IP3K1 is 
an upstream enhancer of S6K signaling, we decided to investigate if this effect was 
conserved in humans.  Small interfering RNAs (siRNAs), designed with IP3KA and 
IP3KB mRNA as target sequences were obtained, along with a non-silencing control  
 (Qiagen).  HeLa cells were transfected with the siRNAs 48 hours prior to stimulation 
using oligofectamine (Invitrogen) and deprived of serum for 16 hours, followed by 
deprivation of amino acids for an additional two hours.  Cells were stimulated by 
amino acids (2X concentration compared to cultivation media) for 30 minutes.  Cells 
were harvested and extracts prepared as described in the “Materials and Methods” 
section.  Standard western blotting techniques were applied to check phosphorylation 
status of S6K at threonine 389, along with total levels of IP3KA, IP3KB, and an actin-
loading control.  The amino acid stimulation resulted in a robust phosphorylation of 
S6K in the non-silencing siRNA control compared to amino acid-depleted conditions, 
however, when IP3KA or IP3KB levels were reduced by siRNA this activation was 
completely inhibited (Fig. 26), indicating that IP3KA is required for the amino acid 
sensing arm of the pathway.   
Next, we wanted to understand if the reduction in TOR complex 1 signaling 
was due the absence of the IP3KA protein itself, or a side effect due to changes in 
concentrations of specific inositol phosphates.  To this end, we applied the IP3 kinase 
inhibitor N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine (Calbiochem) to cells as 
an acute treatment at a 50µM concentration, both in the absence and presence of amino 
acids.  Surprisingly, rather than blocking the amino acid response, the inhibitor  
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Figure 26: siRNA against IP3KA or IP3KB suppresses phosphorylation of S6K 
T389. 
siRNA against targets; non-silencing (NS), IP3KA (A-1, A-2) and IP3KB (B-1,B-2).  
Amino acid deprivation (-AA) suppresses S6K T389 phosphorylation, and add- back 
(+AA) provides a robust stimulation, which is blocked by the siRNA treatment against 
either IP3KA or IP3KB. 
 
upper: p85 
lower: p70 
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stimulated phosphorylation of S6K-389 even in the absence of amino acids (Fig. 27).  
Furthermore, when added in concert with amino acids, the phosphorylation of this site 
was stronger than by re-addition alone.  This unexpected result led us to consider the 
effect of long-term inhibition of the kinase, a situation more analogous to siRNA 
knockdown of the gene product in terms of time.  
Upon long-term (12 hour) treatment with the inhibitor, the stimulation of the 
pathway by starvation and re-addition of amino acids was almost completely 
suppressed, with no phosphorylation observed after starvation alone (Fig. 27).  This 
result demonstrates that the long-term inhibition of IP3K suppresses S6K signaling, so 
it is most likely that it is the loss of kinase activity that causes the effect seen during 
knockdown of IP3KA.  This finding suggests that levels of the inositol phosphates IP3 
and IP4 are important for the S6K signaling pathway. 
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Figure 27: Treatment of HeLa cells with an IP3K inhibitor.  
(A) Short term treatment of HeLa cells with 50µM of an IP3K inhibitor increases 
phosphorylation of S6K T389  at 15 and 30 minutes post treatment, and with a two 
hour pretreatment of inhibitor, while long term inhibition of IP3K (B)  inhibits amino-
acid induced phosphorylation of S6K 
 98 
 
4.3 Discussion: IP3K1 
IP3K1 has a role in growth control 
As with orb2 in chapter one of this thesis, the Drosophila-EP screen initiated by 
the laboratory was aimed at finding novel components of the dS6K pathway, using the 
subtle growth phenotype observed by the over-expression of dS6K to screen for 
modifiers.  Because many EP insertions that caused a modification of this phenotype 
were isolated, it was decided to keep only enhancers producing a similar phenotype to 
DPDK1 upon co-over-expression with the active S6K1dE/D3E (Montagne et al., 
Appendix I, and the chapter on orb2), since these were more likely to be involved in 
the pathway.  The possibility that the Drosophila IP3K1 gene enhances the 
dTOR/dS6K signaling pathway was especially appealing, since the family of IP3 
kinases is very well conserved.  We hoped to show that the modulation of S6K activity 
by IP3K1 was also conserved.   
As the EP13.148 insertion was found to be located in an area with existing 
insertions proven to drive expression of the gene (Fig. 20), we were confident that this 
insertion would be capable of driving IP3K1 expression, rather than disrupting it.  The 
enhancement of the phenotype observed with ap-GAL4, UAS dS6K model was only 
moderate, but appeared to be fully reproducible with a UAS IP3K1 transgene and 
sensitive to titration (Figs. 22 and 23).  Western blotting confirmed an exogenous 
product of the expected size was present in GMR-GAL4 flies with either the EP13.148 
or the UAS IP3K1 (Fig. 24).  After obtaining these results, we hypothesized that the 
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most likely explanation was that the phenotype was related to the catalysis of Inositol 
1, 4, 5-triphosphate (IP3) to Inositol 1, 3,4, 5-triphosphate (IP4), since this is the main 
function of the IP3-kinases [226].  Studies on the IP3K1 gene over-expression had 
previously shown that oxidative stress resistance due to both an EP insertion in the 
gene, and the same UAS IP3K1 construct used in the experiments of this thesis was 
probably due to a decrease in IP3, rather than an increase in IP4 [231]. 
 
IP3R involvement in IP3-mediated calcium response 
IP3 is an important second messenger in the cell, mediating calcium release 
from the internal endoplasmic reticulum stores to the cytosol by Inositol 1, 3,4, 5-
triphosphate receptor (IP3R) binding [232].   More recently, IP3Rs have been 
discovered as having an important role in calcium entry into the cell, being unusual as 
endoplasmic reticulum proteins because they are also functionally expressed at the 
plasma membrane.  In B-cells, as few as two or three receptors per cell at the plasma 
membrane contribute substantially to the Ca2+ entry; accounting for as much as half of 
the influx, with the rest attributable to through the several thousand low-conductance 
store-operated channels [233, 234].  The IP3R has been described as a macro signaling 
complex, functioning as a center for signaling cascades, after identification of  binding 
partners homer, protein 4.1N, Huntington-associated protein-1A, protein phosphatases 
(PPI and PP2A), RACK1, ankaryin, chromogranin, carbonic anhydrase-related protein, 
IRBIT, Na, K-ATPase, and ERp44 [235].  Suprisingly, an EP insertion in the IP3R 
locus also enhanced the ap-GAL4 dS6K bent-down wing phenotype.  This was 
unexpected because we had considered that the over-expression of IP3K would reduce 
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the IP3 pool and as the IP3R requires IP3 binding for its activity, the effect of over-
expression would be the opposite from the IP3K1 phenotype.  With this result, and 
with the knowledge that IP3 regulates calcium signaling, on which S6K activation has 
been shown to be dependent in mammalian cells [236], the question of over-expression 
causing negative effects on the endogenous signaling abilities of IP3K1 was raised.  
We therefore decided to move into cell culture to assess the effect of RNAi on the 
signaling ability of the TOR signaling pathway. 
 
IP3K1 enhances dS6K signaling; the IP3 / IP4 enhancer model 
Considering that reduction of S6K T389 phosphorylation is observed in amino-
acid stimulated cells in both the RNAi knockdown of IP3KA (the mammalian 
homologue of IP3K1, Fig. 26), and the long-term treatment with an IP3 kinase 
inhibitor (Fig 27), it is clear that it should be the over-expression of a functional IP3K1 
that is responsible for the growth enhancement observed in the fly, rather than a 
negative effect. All the evidence for IP3 mediated-events point to a positive role in 
calcium mobilization via the IP3R, either by external entry via the plasma membrane or 
from ER stores the cytosol, thereby amplifying the signal via store-operated calcium 
channels (see above).  Since it has been shown that in IP3KB knock out mouse, IP3 
levels are not significantly increased,  [237], we could assume that the effect of reduced 
S6K signaling by knockdown of the IP3K genes in mammalian cells was due to a 
deficiency in IP4, rather than an increase of IP3.  Although other IP3 kinases still exist 
in the cell, and the inositol polyphosphate kinase 2 (IPK2) can also produce the same 
isomer of IP4 [238], the specificity of spatial or temporal regulation of these proteins is 
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unknown.   Our results indicate that even if there is a competent compensatory 
mechanism for IP3 catabolism in the cell, it is not able to make up for loss of an IP3K 
in terms of S6K1 signaling.   
Although the role of IP3 in calcium oscillations of a cell is well documented, IP4 
was long considered merely a product of IP3 metabolism.  The complicated and 
intriguing question of what function this inositide performs is still highly controversial.  
In a dispatch from Current Biology in 2001 [239], Robin Irvine surmised that it can 
have several roles based on recent evidence; firstly, protection of IP3 from hydrolysis 
through its 10-fold-greater affinity for inositol 5-phosphate phosphatase, whilst 
maintaining relatively high levels in the cells due to a Vmax 100-fold lower than that of 
IP3.  The combination of these factors mean that after IP4 has been produced by 
calcium-signaling pathways, it will be present as a protector of the next episode of IP3 
production.  Secondly, IP4 can behave as an antagonist to the IP3R, if the ratio of 
IP4:IP3 becomes greater than 10:1, enabling re-loading of the ER calcium pools. 
Thirdly, IP4 can specifically and directly activate epithelial and neuronal plasma-
membrane calcium channels, and finally; IP4 is an important precursor for higher 
inositol phosphates such as IP5, IP6, IP7, IP8, and also for regulation of an alternatively 
phosphorylated form of IP4, (inositol 3,4,5,6-tetrakisphosphate) which acts as a second 
messenger controlling chloride efflux.   
By applying this knowledge to our results, one model which emerges is one in 
which over-expression of IP3K1 protein may allow the “priming” step alluded to in the 
above paragraph to occur more readily than at endogenous levels.  This would then 
protect IP3 levels, and the feedback response of calcium signaling would replenish IP3 
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stocks by activation of phospholipase C (PLC), with the end result of normal IP3 and 
elevated IP4 levels in the cell.  Although the increase in IP4 could inhibit the calcium 
activation of IP3Rs, this would also allow accumulation of calcium for future effective 
oscillations.  In this context, TOR/S6K signaling could be enhanced, as it is already 
known that this pathway is regulated by, and dependent on, calcium flux.  Interestingly, 
it could also form part of a positive feedback loop, itself regulating calcium 
oscillations- since mTOR has been shown to potentate calcium release from the IP3R 
in smooth muscle [240]. 
 
IP3K1 enhances dS6K signaling; the IP4 enhancer model 
More recently, a new role for IP4 has been discovered in regulation of protein 
tyrosine kinase Itk by enhancement of an important mechanism which is generally 
required for full activation of a subset of proteins [241].  Pleckstrin homology (PH) 
domain-containing protein recruitment to cellular membranes is mediated in many 
cases through phosphatidylinositol 3,4,5-trisphosphate (PIP3), and regulation of such 
proteins is based on production and turnover of this ligand.  The authors demonstrated 
that phosphorylation of IP3 to IP4 establishes another mode of PH domain regulation, 
through a soluble ligand, which at physiological concentrations promotes the 
interaction between PIP3 and the PH domain of Itk.  This discovery could have 
revealed a general model for the optimization of many PIP3-PH interactions, and 
therefore a requirement for IP4 for the full activation of protein kinases.  If this is 
indeed the case, a new model for the enhancement of S6K/TOR signaling based on the 
interaction between PIP3 and IP4 can be envisaged (see Figure 28).  In this model 
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Figure 28: Proposed model for action of IP4 on S6K/TOR pathway. 
Enhanced signaling through PIP3-IP4 interaction  has downstream consequences 
resulting in amplification of PIP3 and calcium-activated signaling pathways, including 
S6K/TOR signaling. 
mTOR Complex1–S6K1 signaling: at the crossroads of obesity, diabetes and cancer 
Dann, S.G. et al, Trends in Molecular Medicine, Volume 13, Issue 6, June 2007, Pages 
252-259.
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upstream growth factor signaling events activate class 1 PI3K, whose action is this to 
convert PIP2 to PIP3 at the plasma membrane.  PIP3 is required for the proximal 
localization of PKB and PDK1, and this results in the phosphorylation of critical 
residues on PKB.  Meanwhile, active calcium release from the ER, mediated by 
activated TOR would result in IP3K activity towards IP3, and IP4 intracellular 
concentrations would increase. The IP4 produced could then enhance pH domain-PIP3 
interaction, therefore amplifying the signal from the plasma membrane to components 
of the TOR signaling pathway.  This model is supported by preliminary data 
(Appendix IV) that the EP13.148 also rescues the eyeless-GAL4; UAS PTEN-induced 
small-eye phenotype. 
In the case of the IP3KA and B knockdowns, even though the suppressed S6K 
signaling observed is in an amino acid-stimulated context (and therefore separate from 
the growth factor input) this model cannot be excluded.  The reduction in basal levels 
of IP3KA and B prior to stimulation may already have had an effect on the pathway, 
for  example, by alleviating the inhibitory effect of PKB on the TSC1&2 complex, due 
to the reduced potential of PIP3 signaling upstream.   
 
Future work with Inositides and their regulators 
More work is needed to understand the consequences of reducing or increasing 
IP3K activity in the cell.  While there are three IP3 kinases in mammalian cells, it 
appears that removal of a single kinase at one time is enough to cause a perturbation of 
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TOR/S6K signaling.  As IP3 is important for calcium oscillations, we would like to 
know if the S6K/TOR pathway relies on oscillations for their activity, and if the 
frequency of calcium oscillations within a cell can alter the effectiveness of TOR 
signaling, or vice versa.  Over-expression of a kinase-active and kinase-dead form of 
these IP3 Kinases in mammalian cell culture would help us to understand more about 
the role of their second messengers in calcium-induced TOR/S6K signaling.    
In addition, because both IP3 and IP4 appear important the role of IP3K, by 
virtue of the long-term IP3K inhibitor and RNAi treatments (Figs. 26 and 27), along 
with the enhancement of dS6K-mediated growth caused by IP3K1 over-expression, it 
would be interesting to see what effect increased Phospholipase C (PLC) activity has 
on the pathway, as it cleaves PIP2 in order to generate IP3 and DAG.   
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CHAPTER 5: General Discussion 
5.1 Overview 
Using a genetic approach in Drosophila, we were able to identify two 
conserved genes important for S6K-mediated growth.  We found that the orb2 protein 
can not only enhance dS6K-mediated growth, but above a certain threshold, it can also 
suppress it. By including orb2 in the TOR/S6K signaling pathway, we add another 
level of complexity to this model of translational regulation. 
The IP3K1 gene from Drosophila is highly homologous to its mammalian 
counterpart, IP3KA.  IP3KA and IP3KB activity both appear to be important for 
maintaining the signaling events that result in phosphorylation of S6K, and 
demonstrate the importance of IP3, IP4, and calcium signaling in growth-factor and 
amino-acid signaling through mTOR. 
By pursuing the mechanism by which the gene products exert their effect on the 
S6K/TOR pathway, we hope to understand more about the conservation of this 
pathway and ultimately new clues for the treatment of disease.   For example, both of 
these candidate genes have a role in the brain, and potentially in pathological 
conditions of the brain, such as Alzheimer’s disease [242-245], and prion diseases 
[169].  Both are present in dendritic spines, morphological specializations that protrude 
from the main shaft of dendrites. Most excitatory synapses in the mature mammalian 
brain occur on spines [148, 246-249].  It is entirely possible that by understanding 
more about the interactions of these proteins with the TOR/S6K pathway, which is 
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gaining importance in the field of neuroscience [250-253], we may open new avenues 
for the treatment of neurological conditions.   
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ABSTRACT  
The nutrient and insulin signaling pathways play a central role in orchestrating  
cellular growth. These pathways also integrate extrinsic and intrinsic inputs,  
including activity mediated by nuclear receptors and their cognate ligands. To  
identify new regulators involved in the S6Kinase nutrient response we have 
used  
a sensitized phenotype for a gain-of-function genetic screen in Drosophila. We  
found that the nuclear receptor DHR3, known to coordinate metamorphosis, is  
also involved in the control of cell growth. We have demonstrated that this 
effect  
is, at least in part, mediated by regulating dS6K activity but not expression.  
Strikingly, we observed that the ligand-binding domain of DHR3 is required and  
sufficient to control this growth process. We also obtained data supporting the  
existence of a natural DHR3 protein lacking its DNA-binding-domain. Our study  
in Drosophila provides the first molecular evidence linking the dS6K nutrient  
response and a nuclear receptor signal.   
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INTRODUCTION  
During development, the growth process (i.e. increase in cell mass) arrests  
when organs reach their appropriate size {Conlon, 1999 #99}. However, to  
maintain homeostasis in adults, some cells are stimulated to grow. Also,  
perturbation of cell growth can occur in pathologies such as cancers or obesity.  
This indicates that the regulatory system controlling growth can potentially be  
activated in quiescent cells of several adult organs.   
The Drosophila genetic system has been successfully used to investigate the  
molecular mechanisms underlying growth {Edgar, 2006 #74}. These studies  
emphasized the central role of the insulin and nutrition signaling network that is  
conserved throughout evolution {Montagne, 2001 #5}. The identification of  
regulators that affect growth, either in a negative or a positive manner,  
significantly contributed to the understanding of this network both in Drosophila  
and in mammal. Binding of insulin or of a related peptide to its cognate receptor  
induces a kinase cascade that results in the recruitment of the protein kinase B  
(PKB) at the membrane and thereby its subsequent activation {Manning, 2007  
#233}. In this process, the phospho-inositide-3-kinase (PI3K) class I converts  
phosphatidylinositol 4,5-bisphosphate (PIP2) in phosphatidylinositol 3,4,5-  
triphosphate (PIP3) constituting a docking site for PKB. Conversely, the tumor  
suppressor PTEN (Phosphatase and Tensing homolog on chromosome 10)  
catalyzes the opposite reaction.  In Drosophila, activation of PKB provokes  
translocation of the transcriptional repressor, foxo, to the cytoplasm {Puig, 
2006 #116}, and degradation of the tuberous sclerosis complex 2 (TSC2), 
{Gao, 2002 #27; Potter, 2002 #40}. TSC2 heterodimerizes with TSC1 {Potter, 
2001 #37; Tapon, 2001 #144; Gao, 2001 #26} to inhibit the  protein kinase 
target of rapamycin (TOR) through inactivation of the GTPase Rheb {Saucedo, 
2003 #128; Zhang, 2003 #62; Garami, 2003 #185}. Downstream of TOR, 
insulin stimulation provokes activation of S6K, which in turn phosphorylates the  
ribosomal protein Rps6 {Jeno, 1988 #236} {Jefferies, 1997 #242}. Nonetheless,  
TSC2 inactivation mediated by PKB is controversial, as we and others 
demonstrated that the nutrient response and insulin signaling operate on 
parallel pathways to govern drosophila growth {Radimerski, 2002 #4; 
Radimerski, 2002 #3; Colombani, 2003 #1; Dong, 2004 #132}. That insulin 
signaling and PKB play a role in the S6K activation pathway mostly relies on 
over-expression experiments and utilization of inhibitors such as wortmanin 
that blocks PI3K activity. However, the discovery that Vps34, a class III PI3K, 
can regulate S6K in a nutrient-dependant manner and is also wortmanin 
sensitive {Nobukini, 2004  
#31}{Byfield, 2005 #232}, may at least in part explain this controversy.  
The molecular mechanisms that integrate growth, nutrition and morphogenesis  
remain largely unexplained. Indeed, regulators distinct from components of the  
nutrition and insulin signaling networks have been implicated in the growth  
process that underlies development and cancer progression {Vidal, 2006 
#162}.  
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In mammals, these include intermediates in morphogenetic signaling, such as  
TGFβ, hedgehog or Wnt family members {Sancho, 2004 #163}, as well as  
nuclear receptors (NRs) whose activity is regulated upon binding of their 
cognate ligands {Singh, 2005 #164}. Almost 50 NRs are present in human. The 
ligand is known for more than half of them, whereas the others are referred to 
as orphan receptors. Drosophila contains 18 NRs {King-Jones, 2005 #80}, but 
the ligand is identified for only the ecdysone receptor {Koelle, 1991 #214}; the 
RXR homologue, Ultraspiracle, which binds to juvenile hormone JH III {Jones, 
2006 #166} ; and E75, which has recently been shown to interact strongly with 
a heme prosthetic group {Reinking, 2005 #90}. This latter interaction is 
necessary to stabilize the E75 protein and is critical to counteract, in a gas-
dependent manner, the transcriptional activity of DHR3, another Drosophila 
NR.  Together, these NRs orchestrate developmental processes that occur 
during embryonic, larval and pupal life. Although unlikely, it is possible that 
these regulatory modules do not require the insulin/nutrition signaling network. 
More likely is the possibility that the molecular links between these systems 
have simply not been identified yet. In favor of the latter idea, recent 
publications revealed that ecdysone antagonizes insulin signaling {Colombani, 
2003 #1}{Mirth, 2005 #168}{Caldwell, 2005 #167}. The negative input provoked 
by ecdysone is relayed at the fat body (FB, diffuse organ with storage and 
humoral functions) to protect against cytoplasmic inactivation of foxo.  The 
Drosophila life cycle comprises larval stages where endoreplicative tissues  
assume the physiological functions. Within larvae and pupae, imaginal discs  
grow and proliferate prior to the differentiation into adult structures that occurs 
at late metamorphosis. Discs are subdivided into compartments that constitute 
the growth units {Garcia-Bellido, 1976 #172}. In this context, overexpression of 
the Drosophila S6K homologue (dS6K) within the developing dorsal wing  
compartment induced a bending down of the adult wing {Montagne, 1999 #8}.  
Consistent with dS6K playing a positive role in cellular growth, this phenotype 
is due to an increase of the size of the dorsal wing blade. As this phenotype 
can vary with respect to the level of dS6K activity {Radimerski, 2002 #4} 
{Barcelo, 2002 #220}, it has been retained for a gain-of-function genetic 
strategy to identify new components that potentially regulate dS6K activity. In 
this way, we have found that the NR DHR3 acts as a positive regulator of dS6K 
activity.  
  
  
RESULTS  
  
Screening for dS6K modulators  
Overexpression of dS6K within the developing dorsal wing compartment (using  
an apterous-Gal4 [ap-Gal4] driver), induced a bent-down wing in the adult  
(Figure 1A,B) due to a moderate overgrowth of the dorsal wing blade 
{Montagne,  
 v 
1999 #8}. Congruent with PDK1 being the S6K T-Loop kinase {Alessi, 1998  
#178; Pullen, 1998 #177}, we further observed that this bending-down was  
enhanced by co-expression of the drosophila PDK1 (DPDK1), whereas over-  
expression of DPDK1 alone was without noticeable consequence {Radimerski,  
2002 #4}. This epistatic interaction demonstrated that the intensity of the bent-  
down wing phenotype was modified with respect to the dS6K activation status.  
Therefore, we made use of this sensitized phenotype in a gain-of-function  
genetic strategy to identify new components with the potential ability to regulate  
dS6K activity Interestingly, overexpression of an active form of the mammalian  
S6K (S6K1dE/D3E) {Dennis, 1996 #181} induced a bent-down wing phenotype  
identical to that induced by dS6K (Figure 1 B,C). Like dS6K, co-expression of  
S6K1dE/D3E and DPDK1 led to an enhancement of the bent-down wing, but not 
to the extent observed with dS6K (data not shown). This differential phenotypic  
interaction may be a hallmark of specificity, as dS6K, unlike S6K1dE/D3E, is the  
genuine target for DPDK1 {Radimerski, 2002 #4; Rintelen, 2001 #16}. These  
differential effects were utilized to improve the selectivity of the gain-of-function  
screen (see below).  
Overexpression of About 5000 Enhancer-Promoter (EP) bi-directional  
insertions {Reiling, 2004 #32} were induced together with dS6K in the 
developing dorsal wing compartment, and the dS6K-dependent bent-down 
wing phenotype was monitored for enhancement or suppression. To further 
restrict their specificity, about 1000 EP lines that displayed striking phenotypes 
possibly unrelated to dS6K function were then retained and analyzed for their 
effects when induced alone with the ap-Gal4 driver. This subsequent screen 
was designed to eliminate nonspecific modulators that, alone, induced a 
phenotype identical to that obtained in combination with dS6K (data not 
shown). Eventually, 220 lines were tested again to precisely compare their 
effects when induced alone, in combination with dS6K or with the active 
S6K1dE/D3E. The enhancers identified in the screen could be separated into two 
subsets with respect to their interaction with dS6K and S6K1dE/D3E. One subset 
enhanced the bent-down wing phenotype to the same extent in combination 
with either kinase, while the other subset displayed a differential effect that was 
stronger in combination with dS6K than with S6K1dE/D3E (data not shown). As 
DPDK1 belongs to the latter group, we reasoned that candidate enhancers that 
interacted differentially with dS6K and S6K1dE/D3E were more likely to affect 
dS6K signaling, whereas those with no differential response might be involved 
in the general process of wing formation.  
  
Identification of DHR3 as a genetic modulator of dS6K-dependent growth  
As a result of the screen for dS6K modulators, 57 clear enhancer lines were  
retained and 45 of them were molecularly mapped. Ten lines corresponded to 
a “hot spot” for insertions within the regulatory region of DPDK1, which 
confirms the relevance of the genetic screen. In addition, two strong enhancer 
lines (EP12.218, EP23.014) were shown to be inserted within the locus of the 
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NR DHR3 {Koelle, 1992 #186}; these lines are hereafter referred to as EP-
DHR3. Induction of an EP-DHR3 alone using the ap-Gal4 driver was without 
visible consequence, while the combination with dS6K induced a strong 
enhancement of the bent-down wing phenotype (Figure 1A,B,D,E). The EP-
element used in the screen contained two UAS promoters that can direct 
transcription in opposite directions {Reiling, 2004 #32}. Therefore, these two 
EP-DHR3s could potentially induce transcription of either DHR3 or a histidine-
decarboxylase (CG3454). As the UAS promoter driving the latter was flanked 
by lox sequences, the Cre recombinase was induced to excise this promoter. 
When co-induced with dS6K by the ap-Gal4 driver, this novel unidirectional EP-
DHR3 element retained the ability to enhance the bent-down wing phenotype 
(Figure 1J), which rules out the possibility that the histidine-decarboxylase is 
responsible for this genetic interaction.   
Both EP elements were inserted within the first intron (see below) of the DHR3  
gene and, when induced, could potentially either interfere with, or trigger DHR3  
expression. To address this issue, inducible RNA-interference lines (DHR3-  
dsRNAi) were generated to counteract DHR3 expression. Gal4 induction of this  
DHR3-dsRNAi within the developing dorsal wing compartment caused a bent-
up wing phenotype (Figure 1G), indicating that normal growth is affected when  
DHR3 expression is suppressed. Also, when co-induced with EP-DHR3 and  
UAS-dS6K, DHR3-dsRNAi suppressed the bent-down wing phenotype (Figure  
1H,K). Therefore, the genetic interaction with dS6K is due to DHR3 
overexpression, and not to interference with its normal expression.   
EP-DHR3 also enhanced the bent-down wing phenotype when co-expressed  
with the S6K1dE/D3E kinase (Figure 1C,F), but to a lesser degree than when co-  
expressed with dS6K (Figure 1, compare E to F). This suggests that DHR3 
may, like DPDK1, act on dS6K activation. Consistent with this interpretation, 
DHR3- dsRNAi suppressed the bent-down wing phenotype induced by either 
dS6K or S6K1dE/D3E. This suppression was, however, always stronger for dS6K 
than for S6K1dE/D3E (Figure 1, compare H to I). Altogether, these differential 
effects at the bent-down wing indicate that S6K1dE/D3E is less sensitive than 
dS6K to increases or decreases in the dosage of DHR3. As determined for the 
DPDK1 interaction, this argues in favor of DHR3 playing a specific role in 
dS6K-dependent growth. dS6K resides in the nutrient response pathway, in 
parallel to the insulin signaling pathway {Radimerski, 2002 #3; Radimerski, 
2002 #4}. This was demonstrated previously by the finding that dTSC1/2 is the 
dS6K-specific growth suppressor that acts in parallel to the dPTEN/dPI3K 
module. Both dPTEN and the heterodimer dTSC1/2 induced a growth defect in 
the adult eye when overexpressed in the developing eye. As another indicator 
of specificity, co- expression of dS6K counteracted the growth defect due to 
dTSC1/2, but not the one due to dPTEN (data not shown). To further determine 
in which of these pathways DHR3 resides, the EP-DHR3 was induced together 
with either dPTEN or the heterodimer dTSC1/2 in the developing eye. EP-
DHR3 induction alone did not modify eye development (Figure 2A,B). In 
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contrast, induction of EP-DHR3 could suppress the growth defect due to over-
expression of the heterodimer dTSC1/2 (Figure 2, compare D to C). Consistent 
with DHR3 acting in the nutrient response pathway in parallel to the insulin 
receptor pathway, the EP-DHR3 did not counteract the growth defect due to 
DPTEN over-expression (Figure 2, compare F to E). This further argues for a 
tight link between DHR3 and the dTSC/dS6K pathway.  
DHR3 has previously been reported to be an NR that plays a central role in  
coordinating metamorphosis {Lam, 1997 #191; White, 1997 #189}. In addition,  
the bent-up wing phenotype due to DHR3-dsRNAi in the dorsal wing 
compartment indicates that DHR3 is also involved in regulating cellular growth.  
Both EP elements are inserted within the huge first intron of DHR3 (Figure 3A  
and data not shown), and therefore in the absence of Gal4 induction, might  
interfere with DHR3 expression. Indeed, these EP lines failed to complement  
previously reported DHR3 mutants (data not shown). In contrast to these  
previously described DHR3 mutants that are lethal during early development,  
homozygous and trans-heterozygous EP-DHR3 insertions were semi-lethal,  
indicating that they correspond to hypomorphic DHR3 mutants. The few adult  
escapers emerged with about 2 days delay, and displayed female sterility. 
These phenotypic features have also been reported for other mutants that 
affect growth, which confirms that, in addition to coordinate metamorphosis, 
DHR3 also plays a role in controlling growth. Moreover, ubiquitous suppression 
of DHR3 through dsRNAi can provoked either larval death or developmental 
delay (data not shown). Interestingly, suppression of DHR3 targeted to the FB, 
using the pumpless-Gal4 driver, result in a 2 days delay at metamorphosis 
onset (data not shown). As the FB is central in coordinating growth with 
nutrient availability {Britton, 1998 #45; Britton, 2002 #56; Colombani, 2005 
#93}, this latter result further argues for DHR3 acting in the nutrient response 
pathway and thus close to dS6K.  
  
The DHR3 protein that interacts with dSK6 lacks a DNA-binding domain  
DHR3 is an NR that typically comprises an N-terminal DNA-binding domain  
(DBD) and a C-terminal ligand-binding domain (LBD) separated by a linker  
domain {King-Jones, 2005 #80}. Both EP elements are inserted within the first  
intron of the DHR3 gene upstream of the second exon that contains the 
reading frame for the DBD (Figure 3A). All of the DHR3 products reported to 
date are translated from AUGs located in various alternative upstream first 
exons. To identify the DHR3 gene product responsible for the interaction with 
dS6K, RACE PCR has been performed using wild-type and EP-DHR3 larvae 
ubiquitously induced by a daughterless-Gal4 driver (da-Gal4). The transcript 
identified for the latter was a splice variant from the EP to the DHR3 second 
exon, lacking an AUG initiator codon upstream of the sequences encoding the 
DBD (R-EP in Figure 3A and supplementary data). In addition to previously 
described mRNAs, RT-PCR experiments using wild-type larvae allowed the 
identification of a novel DHR3 transcript (RS in Figure 3A and supplementary 
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data). This transcript does not contain a first alternative exon, and most likely 
expresses a DHR3 protein that is devoid of DBD, as the most proximal AUG 
was located beyond the DBD- coding sequence (Figure 3A and supplementary 
data).   
To identify which DHR3 protein is most likely to be responsible for the genetic  
interaction with dS6K, three different UAS constructs were generated, allowing  
the translation of various DHR3 CDS that differ in their N-terminal polypeptide  
sequence. Two of them contain the DHR3 DBD and correspond to the 
previously described PA and PB gene products expressed from the RA and RB 
transcripts respectively (Figure 3A). The other one lacks an upstream 
translational initiator codon, but retains the AUG that potentially allows the 
translation of a DBD- lacking DHR3 protein, hereafter called as SDHR3 (Figure 
3A and supplementary data). When induced by the ap-Gal4 driver, both lines 
expressing a DBD- containing DHR3 protein (PA or PB) result in lethality (data 
not shown). The lethality is certainly not due to the expression in the 
developing dorsal wing compartment, but rather to expression in other tissues; 
for example, the apterous promoter is known to be active in the brain {Herzig, 
2001 #213}. Nonetheless, all other Gal4 drivers tested induced some lethality 
(data not shown). Conversely, in agreement with the RACE PCR results, 
induction of the UAS-SDHR3 line with the ap-Gal4 driver was not lethal and 
phenocopied the enhancement observed with EP-DHR3 (Figure 3C, E). 
Moreover, co-induction of DHR3-dsRNAi led to a loss of the phenotypic 
interaction (Figure 3, compare G to E), which definitively confirmed that SDHR3 
was the gene product responsible for the genetic interaction with dS6K. 
Interestingly, induction of UAS-SDHR3 alone was sufficient to induce a bent-
down wing (Figure 3B,D), and this phenotype could be almost completely 
reverted when DHR3-dsRNAi was co-induced (Figure 3, compare F to D). 
Hence, a DHR3 gene product lacking its DNA-binding domain is able to induce 
growth and to cooperate with dS6K in that process.   
  
DHR3 regulates dS6K activity    
The wing bent-down due to SDHR3 driven by ap-Gal4 (Figure 3D) indicates  
that SDHR3 is sufficient to drive compartment growth. Therefore, an 
experiment on a nil dS6Kl-1 mutant background (some of these flies survive to 
adulthood {Montagne, 1999 #8}) was performed to determine whether dS6K is 
required for induction of the bent-down wing due to SDHR3 driven by ap-Gal4. 
Interestingly, a clear suppression of the bent-down wing phenotype was 
observed in the absence of dS6K (Figure 4, compare B to A), which indicates 
that overgrowth induced by SDHR3 is dependent on the presence of dS6K.   
To further investigate the relationship between DHR3 and dS6K, kinase activity  
was monitored in protein extracts from larvae where DHR3 expression was  
ubiquitously suppressed through dsRNAi, using either a daughterless-Gal4 or 
an actin-Gal4 driver. As depicted in Figure 4C, interfering with DHR3 
expression induced a severe reduction in dS6K activity. The dS6K protein level 
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was not affected (Figure 4D), ruling out a transcriptional effect of DHR3 on 
dS6K expression. Together these results indicate that SDHR3 is able to induce 
growth by modulating the kinase activity of dS6K but not its expression.  
  
In search of a genuine DBD-lacking DHR3 protein  
To determine whether a DBD-lacking DHR3 protein exists naturally, a rabbit  
antiserum to DHR3 was produced using peptides that correspond to 
sequences downstream to the first AUG following the DBD coding sequence 
(supplementary data). Both EP-DHR3 and the UAS-DHR3 lines (Figure 3A) 
were induced by a heat-shock-Gal4 driver (HS-Gal4) during larval life. Although 
larvae expressing a DBD-containing DHR3 protein were dead within a day after 
heat shock, it was possible to prepare larval extracts a few hours after heat 
shock and to analyze them by Western blotting. The UAS-SDHR3 and both 
EP-DHR3 produce a protein that migrates to the same position, corresponding 
to the expected size for a DHR3 polypeptide lacking its DBD (Figure 5A). In 
agreement with the genetic data showing that, by itself, UAS-SDHR3 driven by 
ap-Gal4 is sufficient to induce a bending down of the wing, the amount of 
protein was much higher with UAS- SDHR3 than with EP-DHR3 (Figure 5A). 
Therefore, the expression level of SDHR3 induced by HS-Gal4 correlates with 
the wing phenotype observed with ap-Gal4 driver.  
The larvae that expressed DBD-containing DHR3 constructs (RA and RB)  
displayed differential results (Figure 5A). DHR3-RA produced a single protein  
that migrated at the expected molecular weight for a DBD-containing DHR3. In  
contrast, DHR3-RB allowed the translation of 2 polypeptides; one of them  
migrating roughly to the position of a DBD-containing DHR3, while the other  
polypeptide migrated to the position of SDHR3 (Figure 5A). Therefore, the  
DHR3-RB transcript permitted the translation of 2 proteins that most likely differ  
in whether or not they contain the DBD of DHR3. The levels of expression of  
these two different DHR3 polypeptides are very high and reproducible, which  
rules out that the lower one might be a degradation product. However, we can  
not conclude whether it corresponds to alternative translational initiation or 
post- translational processing of a DBD-containing DHR3 protein.   
To better detect the genuine proteins, extracts were then prepared during  
prepupal stages, as DHR3 has previously been described to be highly 
expressed at the onset of metamorphosis in response to ecdysone signaling 
{Koelle, 1992 #186}. Although purified, the antibody might recognize some 
unrelated DHR3 protein. To unambiguously identify the bona fide DHR3 
protein, extracts were also made from prepupae that ubiquitously expressed a 
DHR3-dsRNAi using a da-Gal4 driver. When induced, the DHR3-dsRNAi often 
resulted in larval lethality, although development sometimes proceeded with 
some delay (data not shown).  
Western blot analysis revealed 2 bands that decreased upon DHR3-dsRNAi  
expression (Figure 5B), suggesting that 2 different DHR3 products are 
expressed in the prepupa. The higher band was at the position of the DBD-
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containing DHR3, whereas the lower band was at the position of the DBD-
lacking DHR3. It is unlikely that the lower band is a degradation product of a 
full-length DHR3 protein, since both proteins were observed in 5 distinct 
experiments with always the same ratio. This protein is most likely produced 
from the RB transcript that allows the translation of 2 distinct DHR3 
polypeptides (Figure 5A). Alternatively, the SDHR3 protein might be translated 
from the messenger species devoid of upstream AUG, which has been 
identified by RACE-PCR experiments (see above and Figure 3A), if this mRNA 
is not a degradation product.  
The antibody has then been used to detect over-expressed SDHR3 protein  
directed by the engrailed-Gal4(en-Gal4) and ap-Gal4 drivers, which are active 
in the posterior and anterior wing-disc compartments respectively. Activation of  
UAS-SDHR3 by the en-Gal4 driver was associated with a UAS-GFP, allowing  
double immuno-staining that revealed a perfect match of GFP and SDHR3  
expression (Figure 5C, D, E). When induced by the ap-Gal4 driver, both the  
UAS-SDHR3 and the EP-DHR3 provoke an increased of the immuno-staining 
to DHR3 restricted to the dorsal compartment (Figure 5C, G, H, I). However, 
the signal was much higher with UAS-SDHR3 than with EP-DHR3 (Figure 5 
compare G to I). Since UAS-SDHR3 but not EP-DHR3 provokes a bent-down 
of the wing when induced alone by ap-Gal4 (compare Figure 1D to 3D), these 
results indicate that SDHR3 can induce growth in a dosage-dependent manner.  
Finally, the antibody was used for detection of the genuine DHR3 protein. To  
guarantee the specificity of the immuno-staining, flip-out clones directing 
DHR3- dsRNAi were generated, and a UAS-GFP was used to positively label 
these clones. A very weak but uniform staining could be detected in both 
imaginal discs and FB from mid-third instar larvae (data not shown). This 
staining may reflect some unrelated background since we could not observe a 
significant decrease in GFP-positive flip out clones that direct DHR3-dsRNAi 
(data not shown). In contrast, the staining observed in prepupal discs was 
stronger and was decreased in flip-out clones, although not totally abolished 
(Figure 5J,K). Again, the remnant staining may reflect unspecific background or 
the moderate effect of dsRNAi in repressing DHR3 expression (Figure 5B). 
Clones displaying a decrease of this specific staining could be detected in all 
imaginal discs from prepupae (data not shown), indicating that DHR3 is widely 
expressed at this stage. In summary, the antibody is able to detect the genuine 
DHR3 protein in prepupae but not in larval tissues. This might suggest that 
DHR3 is not expressed in larvae. However, the developmental delay at 
metamorphosis onset due to either ubiquitous or FB restricted DHR3-dsRNAi 
suggests that a DHR3 product is required for larval development. Nonetheless, 
this expression might be very low, stage specific or restricted to certain tissue, 
since we were unable to detect DHR3-specific staining in endoreplicative or 
imaginal tissues of third instar larvae.  
  
Generation of LBD-specific DHR3 mutants  
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An EMS revertant screen was performed to gain further insights into the protein  
domain of DHR3 required for its growth function with respect to dS6K. EP-
DHR3 males were fed EMS and crossed to females bearing the UAS-dS6K 
and the ap- Gal4 driver. In the offspring, flies that had lost the ability to 
enhance the bent- down wing phenotype were selected for further analysis. 
About 50,000 individual flies were screened to eventually establish 8 lines that 
had clearly lost their ability to cooperate with dS6K in producing the bent-down 
wing phenotype (Figure 6A,B,C). After remobilization of EP-element, only 2 of 
them displayed homozygous lethality and did not complement previously 
described DHR3 mutants (Figure 6G). Nonetheless, both homozygous viable 
and lethal revertants were used to prepare DNA and to sequence the DHR3 
coding region. None of the homozygous viable revertants displayed DNA 
mutations. In contrast, the two DHR3-noncomplementation lines contained a 
stop codon at position 243 and 284, hereafter referred to as DHR3K243X and 
DHR3W284X (Figure 6D and supplementary data).   
Remobilization of the EP element may provoke imprecise excision, creating a  
putative deficiency within the DHR3 locus. Hence, for a deeper phenotypic  
analysis, in order to ascertain that the phenotype could not be due to an  
accidental deficiency, several lines for each DHR3 mutation were generated 
from independent remobilization events. Therefore, eight and ten independent 
lines for DHR3K243X and DHR3W284X, respectively, were used for additional 
genetic tests. All of them were homozygous lethal, failed to complement each 
other, and neither complemented the previously described DHR3G60S and 
DHR3R107G  mutants that affect the DBD (data not shown). All of these mutants 
combination die as embryo indicating that the LBD is essentially required for 
the transcriptional function of DHR3. However, searching among thousands of 
larva, it has been possible to find very few DHR3K243X/DHR3W284X mutants that 
survive until second larval instar. These larva were then use to perform kinase 
assays for dS6K. Congruent with the assay from DHR3-dsRNAi extracts 
(Figure 4C,D) a significant drop of activity but not of dS6K expression was 
observed (Figure 6E, F). This result indicates that the LBD of DHR3 is required 
to regulate dS6K activity, and further suggests that a specific ligand binds 
DHR3 to regulate its functions.  
  
The ligand-binding-domain of DHR3 is required for cell-autonomous 
growth  
To deeply analyze the function of DHR3 with respect to cellular growth, both  
LDB mutants were fused to an FRT and analyzed for cell autonomous function.  
First, these FRT-associated mutations were recombined in the eye disc using 
the eyeless promoter to drive the flipase recombinase during the entire process 
of eye development. As the FRT chromosome arm in front of the DHR3 
mutation contained a homozygous cell-lethal mutation {Oldham, 2000 #6}, the 
recombined sister cells, wild type for DHR3, were eliminated during 
development leading to eyes mostly made up of homozygous DHR3 mutant 
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cells. With both DHR3K243X and DHR3W284X mutations, a moderate but 
significant reduction of the eye size was observed (Figure 7A-C) indicating that 
DHR3 controls growth in a compartment autonomous manner. The flipase 
recombinase was also induced by heat shock. Various homozygous markers 
were used to identify homozygous DHR3 mutant cells. Within third instar  
imaginal discs, clones analyzed 3 days after heat shock did not show visible  
growth defect as compared with the wild-type sister clone (data not shown). As  
well it was not possible to observe significant cell size reduction by FACS  
analysis (data not shown). In contrast, using a yellow marker to look at adult  
tissues, homozygous DHR3 mutant clones, identified by their yellow color,  
displayed a significant reduction in size (Figure 7D). As the hair corresponds to 
a single cell, we can conclude that this mutant cell was reduced in size. These  
DHR3 homozygous mutant bristles were also affected in their orientation, as  
compare to the surrounding bristles. This phenotypic missorientation was also  
observed for the ommatidia-associated bristles (insets in Figure 7A-C) and 
might reflect one of the pleiotropic functions of DHR3. Together, these 
observations indicate that DHR3 acts in a cell-autonomous manner for various 
cellular functions. In particular, we have demonstrated here that the control of 
growth requires the ligand-binding domain, suggesting that DHR3 activity 
depends on binding of a specific ligand.  
  
  
DISCUSSION  
  
How DHR3 does regulate growth and dS6K activity?  
Using the powerful drosophila genetic system in a gain-of-function strategy, we  
have fond that the NR DHR3 acts positively on dS6K activity. DHR3 was  
previously known to coordinate metamorphosis {Lam, 1997 #191; White, 1997  
#189} and we demonstrated here that it also controls cellular growth in a cell  
autonomous manner. Precisely, we have found a new DHR3 polypeptide 
devoid of DBD (SDHR3), and demonstrated that this polypeptide is sufficient to  
genetically interact with dS6K. When strongly over-expressed, SDHR3 can 
drive cellular growth alone. This process requires dS6K, and we further 
demonstrated that disruption of DHR3 provokes a drop of dS6K activation but 
not expression.  
The DBD of NRs is typically made off two Zing-finger, with the first one being  
critical for the specificity of DNA binding {Umesono, 1989 #215}. NRs lacking  
DBD have been previously reported. In drosophila, the E75A an E75B 
polypeptides, which differ in their amino-terminal region, may physically interact  
with DHR3 to repress transcription {White, 1997 #189}{Reinking, 2005 #90}. In  
contrast to E75A, E75B lacks one of the 2 zing-fingers that together are 
necessary to form a functional domain to bind DNA {Bialecki, 2002 #83}. E75B  
however, retains the property to interact with DHR3, thereby modulating its  
transcriptional activity in a gas responsive manner {Reinking, 2005 #90}. As 
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well  
in mammals, the NR, SHP, is totally devoid of DBD and interacts with other 
NRs to inhibit their transcriptional activity {Seol, 1996 #205}. As NRs often 
make homo- or hetero-dimer to regulate transcription {McKenna, 2002 #206}, it 
is conceivable that SDHR3 physically interacts with another NR that provides 
the DNA-binding function. In that case, SDHR3 protein would modulate 
transcription, either to repress a dS6K-repressor or to activate a dS6K-
activator. If they exist, extensive analysis through micro-array would help to 
identify these potential relaying regulators. Nonetheless, we can exclude that 
SDHR3 behaves as a dominant-negative component to the full-length DHR3, 
since SDHR3 over- expression provokes growth, while dsRNAi to DHR3, in the 
opposite, inhibits growth. Two nuclear receptor family members have been 
reported to heterodimerize with DHR3; and this could at least in part explain 
the growth related function of DHR3. As mentioned above, E75 polypeptides 
negatively modulate DHR3 activity {Reinking, 2005 #90}. Therefore, SDHR3 
might titter out these polypeptides, thereby allowing an increase of the 
transcription induced by the endogenous DHR3 bound to its DNA targets. The 
second nuclear receptor know to dimerize with DHR3 is the ecdysone receptor 
(EcR). Both DBD-lacking and full length DHR3 proteins have been show to 
dimerize with the Ecdysone receptor to repress transcription {White, 1997 
#189} and thus, could counteract growth-negative regulation of Ecdysone 
signaling {Colombani, 2005 #93}. However, this is in contradiction with the 
observation that dsRNAi disruption of DHR3 results in a growth defect. 
Alternatively, it is tempting to speculate that SDHR3 activates dS6K through a 
nongenomic process. Such effects do not require DNA-binding and were first 
described as processes for which, the delay of the specific response was not 
compatible with a transcriptional mediation {Losel, 2003 #210}. Nongenomic 
effects typically occur in the few minute following addition of the cognate ligand 
and are resistant to transcriptional inhibitors. Experimentally, we are unable to 
challenge this issue, not only because we use genetic events early induced to 
eventually observe the consequence once development is achieved, but 
because the DHR3 ligand is yet unknown. This hypothesis is however 
attractive, since in mammals, the Vitamin D Receptor (VDR) has been shown 
to modulate S6K1 phosphorylation in a none- genomic manner {Bettoun, 2002 
#209} {Bettoun, 2004 #207} {Lal, 2005 #244}.  
Identification of all the potential partners for SDHR3 will be required to precisely  
determine in what extend, these molecular processes may explain how SDHR3  
regulates growth.  
  
Expression and function of DHR3 during larval life  
We have shown that beside essential function during early development, DHR3  
is required for larval growth, since ubiquitous dsRNAi to DHR3 induces either  
lethality or delay at metamorphosis onset. We also clearly demonstrated that 
the lack of the DHR3 LBD results in autonomous cell size reduction of adult 
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tissues. This effect is likely to result on the decrease of dS6K activity, as we 
previously demonstrated that dS6K controls cellular growth in a cell-
autonomous manner {Montagne, 1999 #8}. The size reduction was however 
stronger in previously described dS6K mutant clones {Montagne, 1999 #8}, 
possibly because dS6K activity is partially suppressed but not abolished in 
DHR3 LBD-mutant larvae. Likewise, the undetectable protein level 
(unpublished results) in a dS6K P- element induced mutation 
P{PZ}S6K[07084]) is sufficient to partially restore the functional activity, since 
this dS6K mutation induced a moderate phenotype as compare to the nil 
mutation {Montagne, 1999 #8}. Nor FACS analysis of cells dissociated from 
wing discs, neither observation of imaginal discs, led to visible size or growth 
defect of DHR3 homozygous mutant clones analyzed in third instar larva (data 
not shown). This may suggest that DHR3 is not involved in cell- autonomous 
growth during larval life. Noteworthy, growth defects could neither be observed 
in dS6K clones of third instar larvae, unless they were induced 4 days before, 
during embryogenesis (unpublished results). Such a strong delay indicates that 
strong dS6K extinction is necessary to generate a visible phenotype in imaginal 
tissues during larval life. Hence the remnant dS6K activity retained in DHR3 
mutant clones might be over a certain threshold that is sufficient to support a 
roughly normal growth in larva. Alternatively, since SDHR3 is almost 
undetectable in mid third instar larva, it is possible that it is not required  
for dS6K activation in imaginal tissues during the period of larval growth. This 
is however unlikely, since we have shown that dS6K activation drops in second  
instar DHR3 mutant larvae. Beside, DHR3 may also retain some systemic  
function, since DHR3-dsRNAi targeted to the FB also provokes a delay at  
metamorphosis, although we were unable to detect significant DHR3 protein  
expression in mid-third instar FB. As well, dS6K is involved in the systemic  
control of growth, as the defect due to FB disruption of the amino-acid 
transporter slif is override by overexpression of dS6K within the FB 
{Colombani, 2005 #93}.  
In summary, both dS6K and DHR3 have a systemic and a cell-autonomous  
function in growth, the latter being difficult to distinguish before metamorphosis.  
Hence, it is possible that larval defect is mostly due to a systemic function of  
DHR3, whereas the phenotype observed in adults revealed a cell autonomous  
function occurring at metamorphosis.   
  
Is there a ligand for DHR3?  
Our data provide the first evidence that the LBD of DHR3 is required to achieve  
a function related to growth, although DHR3 participates in several additional  
functions as homozygous mutation of the DBD provokes embryonic death  
{Carney, 1997 #193}. Interestingly, the none-complementation between LBD 
and DBD mutants indicates that the LDB domain is also required for the 
essential function of DHR3 related to transcription. This strongly supports the 
notions that a ligand exists for DHR3 and that this ligand is required for DHR3 
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pleiotropic activities. Nuclear receptors that bind steroid hormones are high 
affinity receptors, whereas low affinity receptors bind ligands present in high 
concentration as food- provided lipids {Berkenstam, 2005 #234}. In light of a 
recent report, this ligand must be widely present since a fusion of the DHR3 
LBD with the DBD of Gal4 is functionally active in transcription in many 
embryonic and larval tissues {Palanker, 2006 #76}. This heterologous Gal4-
DBD/DHR3-LBD transcription factor is active  
in tissues that provide basal nutrients in particular in a group of cells of the 
larval midgut that is essential for the transfer of nutrients into the hemolymph 
{Palanker, 2006 #76}. We previously demonstrated that dS6K activity is 
regulated by food- provided amino acids {Oldham, 2000 #6}. Therefore it is 
tempting to speculate that dS6K receive another nutrient input through the 
DHR3 ligand. The ligands for the mammalian homologues RORα and RORβ 
have been shown to be the cholesterol {Kallen, 2002 #212} and the long chain 
stearic fatty acid {Stehlin, 2001 #216} respectively. However, predicted models 
of structure indicate that the size of the ligand-binding pocket of DHR3 is 
smaller {Stehlin, 2001 #216}. Thus, DHR3 is likely to be a low affinity receptor 
for an abundant food-provided ligand. Nonetheless, it will be of fundament 
interest to further investigate this issue, as lipid metabolism and the TOR/S6K 
nutrient responsive pathway play a critical role in disease such as diabetes and 
cancers in humans.  
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EXPERIEMENTAL PROCEDURES  
Genetics  
The following fly strains were used: dS6Kl1 and UAS-dS6K, ap-Gal4 
{Montagne, 1999 #8}, UAS-dTsc1/2 {Tapon, 2001 #144}, UAS-dPTEN {Huang, 
1999 #39}, pumpless-Gal4 {Colombani, 2003 #1}, ; DHR3G60S, DHR3R107G 
{Carney, 1997 #193}; eyeless-Gal4 {Hauck, 1999 #221}; Cre-lox (Hafen); 
daughterless-Gal4, actin-Gal4, engrailed-Gal4,UAS-GFP, HR46(K10308), 
FRT-42D,M(2)53, FRT-42D,P(y+)44B (Bloomington stock center). Since y+ 
and w+ markers were used, all the experiments were performed in a y,w 
genetic background.  About 5000 EPy+ independent insertion {Reiling, 2004 
#32} were mated to ap- Gal4>UAS-dS6K virgin females and screened for 
enhancement and suppression of the bent-down wing phenotype.   
For the EMS revertant screen, about 500 EP-DHR3 males were starved over  
night and then transferred on wet paper containing a mM EMS solution in 10  
mg/ml sucrose. After one day these males were mated to about 1500 ap-  
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Gal4>UAS-dS6K virgin females. Flies were then transferred every day for egg  
laying. An estimation of 150.000 F1 flies were obtained; as both parental lines  
were balanced over a CyO chromosome, about 50.000 flies were screened for  
the reversion of the bent-down wing phenotype.   
  
Molecular Biology   
Location of the EP-insertions was performed as described {Reiling, 2004 #32}.  
To generate UAS-DHR3-dsRNAi, a PCR fragment spanning the DHR3 reading  
frame from Leu114 to Lys265 was cloned as described {Reichhart, 2002 #203}.  
Congruent results were obtained, by repeating the experiments with 2 other  
distinct UAS-DHR3-dsRNAi strains provided by H. Tricoire and the National  
Institute of Genetics (http://www.nig.ac.jp/). For RACE-PCR, poly A+ cDNA 
were obtained using RNAeasy kit and Oligotex mRNA purification (both from 
Qiagen) and then amplified with SMART TM RACE cDNA Amplification Kit 
(Clontech). 5ʼ RACE to obtain endogenous cDNAs and the chimeric EP-DHR3 
cDNAs followed a 2-step process : first using a DHR3-specific primer 
(catggtctgctgtggcgtcacggaggc) and universal primer mix, then by nested PCR  
using a combination of nested universal primer mix/ DHR3-specific primer  
(cggttgcgattaacacggtccaccac). UAS-dE/D3E and DHR3 cDNAs were clones in  
pUAST vector and injected as previously described {Montagne, 1999 #8}. the  
RA-cDNA was kindly provide by Carl Thummel; the  RB-cDNA  was obtained  
from DHRC; the RS transcript was artificially generated by truncation of the RA-  
cDNA, lacking AUG initiator codon upstream of the DBD coding sequences. To  
identify EMS point mutations, DHR3 coding sequences were PCR-amplified 
from genomic DNA of revertant flies. Fragments were then sequenced and 
search for double picks as compared to wild type genomic DNA. Identified point 
mutations were confirmed by independent repetition of the entire procedure.   
  
Observation  
Larval tissues were dissected, stained as previously described {Montagne,  
1999 #8}, and observed on a Leica Sp2 confocal microscope. For SEM, flies  
were fixed by successive baths of increased ethanol concentrated solution up 
to 90%, and directly observed on an S-3000N HITACHI scanning-electron  
microscope.   
  
Biochemistry  
Protein extracts and Western blotting were performed as previously described  
{Oldham, 2000 #6}. For timing determination of prepupal stages, wondering  
larvae of the corresponding phenotype were collected and transferred to a new  
tube. Newly formed prepupae and late third instar larvae were collected to 
make protein extracts. In vitro dS6K kinase activity assay from second instar 
larval extracts were performed essentially as described {Oldham, 2000 #6} 
using histone H2B as substrate {Reinking, 2005 #90}. The antiserum to DHR3  
has been produced by Eurogenetec Company.  
 xvii 
The peptides 144 QMRAQSDAAPDSSYYD159 and 209SADYVDSTTYEPRSTI224 
were used to immunize a rabbit. The specific antibodies were then affinity 
purified as previously described {Stewart, 1996 #219}.  
  
  
FIGURE LEGENDS  
FIGURE 1: DHR3 is a specific dS6K interactor. The ap promoter directs Gal4  
expression within the dorsal compartment of the wing imaginal disc (A) to 
induce UAS-dS6K (B, E, H,J,K), UAS-mS6KdE-D3E (C,F,I), EP-DHR3 (D, E, F), 
UAS- DHR3-dsRNAi (G,H,I,K) and a unidirectional EP-DHR3 (J). The bending-
down of the wing indicates a slight overgrowth of the dorsal compartment, 
whereas a bending-up reveals a slight growth defect of this compartment.  
  
FIGURE 2: The EP-DHR3 counteracts dTsc-dependent growth suppression.  
The eyeless promoter directs Gal4 in the developing eye (A) to induce EP-
DHR3 (B,D,E), UAS-dTsc1 and UASdTsc2 (C, D) and UAS-dPTEN (E, F).    
  
FIGURE 3: The DHR3 protein that genetically interacts with dS6K does not  
contain DNA binding-domain. (A) The locus of DHR3 is represented at the top  
with the 2 EP insertions (arrows); at least 4 different transcripts have been  
reported (RA, RB; RC and RD are not represented here).  RS is a putative 
novel transcript whose first AUG is located beyond the DBD coding sequences 
(grey box). The various polypeptides (black and grey boxes) mostly differ in 
their N- terminus; RS and R-EP potentially allow the translation of the SDHR3 
product. (B-G) Gal4 is expressed in the developping dorsal wing imaginal discs 
(B), to induce dS6K (C), SDHR3 (D) or both (E). Induction of a dsRNAi to 
DHR3 suppresses the bending down wing phenotype due to SDHR3 alone (F) 
or in combination with dS6K (G).  
  
FIGURE 4: DHR3 is a positive regulator of dS6K activity. (A, B) SDHR3 is over-  
exppressed in the developing dorsal wing compartment; this induces a bent-  
down of the adult wing (A) that  is suppressed in dS6K mutant escaper (B). (C)  
Ubiquitous induction of a double-stranded interfering RNA to DHR3 (RNAi) 
using either a daughterless-Gal4 (da>) or an actin-Gal4 (ac>) drivers, provokes 
a drop of dS6K activity, as compared to control drivers alone (da, ac); (D) 
Western-blot to dS6K indicating that dsRNAi to DHR3 has no effect on dS6K 
expression; (E) Western-blot to α-tubulin as a loading control.  
  
FIGURE 5: Immuno-detection of DHR3 proteins. (A) western-blotting using a  
rabbit antibody to DHR3 with protein extracts from heat shock induced UAS 
lines expressing the RA, RB transcripts, or the EPs (E1 and E2); SDHR3 is 
produced from a UAS construct whose most proximal AUG is located beyond 
the DBD (see Figure 3 for the various transcripts). The arrows at the left 
indicate the position of the DBD-containning (high) and DBD-lacking (low) 
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DHR3 proteins. (B) western- blotting to the endogenous DHR3 protein in late 
third instar larvae (L3), prepupae (pp), and prepupae expressing a dsRNAi to 
DHR3 (RNAipp); SDHR3 is as in (A) but the membrane is over-exposed to 
detect genuine DHR3 proteins. (C-K) Wing  
imaginal discs stained with DAPI (C, F, H), antibody to DHR3 (D, G, I, K) and  
antibody to GFP (E, J). (C-E) Over expression of UAS-SDHR3 and USA-GFP 
in  
the posterior compartment, using an engrailed-Gal4 driver. (F, G) Over  
expression of UAS-SDHR3 in the dorsal compartment using the ap-Gal4 driver.  
(H, I) Induction of the EP-DHR3 in the dorsal compartment using the ap-Gal4  
driver. (J, K) Flip-out clone in prepupal wing imaginal disc expressing a dsRNAi  
to DHR3 and a UAS-GFP; the clone was induced 3 days prior dissection; note  
the visible decrease of DHR3 staining (K) in the clone labeled by GFP (J),  
indicating that DHR3 is  expressed in this tissue.  
  
FIGURE 6: Generation of EMS mutations in the LBD of DHR3. (A-C) The ap-  
Gal4 driver induces both the UAS-dS6K and the EP-DHR3 transgenes; this  
provokes a bent down of the wing (A) that is lost when the EP directs the  
expression of the EMS DHR3 mutations (B, C) generated in the revertant 
screen. (D) Structure of the full-length DHR3 protein showing previously 
described DBD mutants (G60S, R107G) and the EMS-mutants that disrupt the 
LBD (K243X, W284X); the light and dark grey boxes represent the DBD and 
the LBD respectively. Measurement of dS6K activity (E) and corresponding 
western-blot to dS6K (F) in the trans-heterozygote LBD-mutant combination 
(LBD), as compare to heterozygous control (Co).   
  
FIGURE 7:  DHR3 regulates growth in a cell-autonomous manner.(A-C) The  
eyeless promoter directs the flipase recombinase during eye development. The  
flipase allows recombination on the right arm of the second chromosome and  
eventually leads to an adult eye that is homozygous for the wild type allele of  
DHR3 (A); homozygocity for each LBD-DHR3 mutation (B, C) results in a  
decrease of the size of the adult eye; a doted yellow line surrounding the 
control eye (A) has been copied and pasted on the mutant eyes (B,C); insets 
are higher magnification of ommatidies showing misorientation of bristles. (D) 
An heat shock induced LBD-DHR3 mutant bristle (arrow) that is visible with 
respect to its yellow genetic marker (arrow) has smaller size as compare to the 
surrounding bristles.    
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APPENDIX II:  
OVER-EXPRESSION OF DS6K RESULTS IN 
INCREASED LEVELS OF PHOSPHORYLATED DS6K 
 
 
 
 
 
 
Overexpression of a dS6K transgene alone and with various UAS orb2 
transgenic flies using Elav-GAL4.  In all cases, where there is overexpression 
of dS6K, phosphorylation of dS6K serine 398 follows suit. 
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APPENDIX III:  
HEAT-SHOCK INDUCTION OF ORB2  
 
 
 
 
Overexpression of orb2 transgenes using Heat-Shock-GAL4 (HS-GAL4).  
Lane 1= HS-GAL4, 2= HS-GAL4, UAS orb2-PB (CL2), 3= HS-GAL4, UAS orb2-PA 
(CS7), 4= HS-GAL4, UAS orb2-PB (CL5), 5= HS-GAL4, EP orb2.  Note that the UAS 
orb2-PB (CL5) line was the line which reproduced the bent-down wing phenotype of 
ap-GAL4, UAS dS6K, EP orb2. 
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APPENDIX IV:  
EYELESS-GAL4, UAS PTEN; EP IP3K PHENOTYPE 
 
 
 
 
a) Eyeless-GAL4 b) Eye-GAL4, EP IP3K1 c) Eye-GAL4, UAS PTEN d) Eye-
GAL4, UAS PTEN; EP IP3K1 
